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Background: Atopic dermatitis (AD) is one of the most common chronic skin disorders 
globally. It is an itchy inflammatory skin disease that can have a detrimental impact on 
health-related quality of life. In recent years, AD has been associated with non-atopic 
conditions, though this requires further exploration. Novel understanding of AD pathogenesis 
has recently led to development of the first biological treatment. The overall aims of the 
thesis were to assess cardiovascular disease (CVD), autoimmune disease and depression 
among adults with AD, and to investigate the response to, and some adverse events from, 
systemic treatment that includes the first biological for AD. 
Methods: Register-based, case-control studies were conducted to assess CVD and 
autoimmune comorbidity among patients with AD. The source population comprised the 
entire Swedish population aged ≥ 15 years. Cases, including all those with an inpatient 
diagnosis of AD (from 1968) and/or a specialist outpatient diagnosis of AD (from 2001) 
through 2016, were matched by sex and age to healthy controls (104,832 cases of AD, 
1,022,435 controls). Patients were classified as having severe AD if they had received 
systemic pharmacotherapy for AD or had been treated in a dermatological ward with AD as 
the main diagnosis. Otherwise, AD was classified as non-severe. The clinical cohort studies 
and the case-series used data from a register containing prospectively collected data from 
adult patients with AD on systemic treatment at the Karolinska University Hospital from 
2017. The register was launched for national use in 2019. 
Result: Studies I–II: After multivariable adjustments for comorbidities and socioeconomic 
status, AD was associated with angina pectoris (adjusted odds ratio (aOR) 1.13, 95% 
confidence interval (CI) 1.08–1.19). Non-severe AD was associated with myocardial 
infarction (aOR 1.15, 95% CI 1.07–1.23) among men. Severe AD was associated with 
ischaemic stroke, with similar estimates in men and women (aOR 1.19, 95% CI 1.07–1.33). 
Diabetes mellitus, hyperlipidaemia, and hypertension were more prevalent in patients with 
severe AD than in controls, and hyperlipidaemia and hypertension were also more prevalent 
in patients with non-severe AD than in controls. Having AD was significantly associated with 
having one or more autoimmune diseases as compared with controls: (aOR 1.97, 95% CI 
1.93–2.01), and this association was significantly stronger for having multiple autoimmune 
diseases than for having only one. The association was strongest for autoimmune disorders 
involving the skin, the gastrointestinal tract or the connective tissue. Studies III–V: In a case-
series of 10 patients with severe, long-lasting AD and most often also previous eye disease, 
9/10 developed eye complications during dupilumab treatment, most commonly 
conjunctivitis (7/10). In a cohort study of patients treated with dupilumab (n = 12), weight 
gain (mean 6.1 kg, range 0.1–18.0 kg, p = 0.002) was seen after 1 year on treatment. In spite 
of these adverse events, dupilumab was very effective and safe. More than half of patients 
with moderate-to-severe AD eligible for systemic treatment (n = 60) had depressive 
symptoms, 25% of whom presented with moderate-to-severe depression and 5% of whom 
had pronounced suicidal ideation. Systemic treatment for AD significantly reduced 
depressive symptoms, in addition to relieving symptoms of AD. 
 
Conclusion: AD was associated with CVD and several autoimmune disorders. More than 
half of the patients with moderate-to-severe AD in routine dermatological care had depressive 
symptoms. Dupilumab was very effective and safe overall, but was associated with ocular 
adverse events and weight gain in these small studies. Systemic treatment for AD 
significantly reduced depressive symptoms in parallel with reducing AD symptoms. 
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Atopic dermatitis (AD), also known as atopic eczema, is a common chronic inflammatory 
skin disease. Depending on its severity, AD can have a detrimental impact on health. There 
is increasing evidence for an association between AD and several non-atopic comorbidities, 
although causative mechanisms are largely unknown. Increased understanding of AD-
associated comorbidities, in combination with reduction of risk factors, may aid prevention 
of certain comorbidities. Moreover, there has long been a lack of effective, safe and long-
term treatments for moderate-to-severe AD. Novel understanding of AD pathophysiology 
has led to rapid development of new AD therapies, including biological therapies. The first 
biologics have recently been introduced and it seems that a new era with target-specific 
treatment has just begun. There is a need for more knowledge on the benefits and safety of 
new and emerging therapies. 
The overall aims of the thesis were to assess cardiovascular disease (CVD), autoimmune 
disease and depression among adults with AD, and to investigate the response to, and some 




2 LITERATURE REVIEW 
2.1 ATOPIC DERMATITIS 
2.1.1 Nomenclature of AD 
The earliest description of what may have been AD is found in the Roman historian 
Suetonus’ description of Emperor Augustus (from 69 A.D.) (1). The emperor suffered from 
cardinal features of AD, such as intense pruritus and eczematous lesions. During the 20th 
century, many names have been proposed for AD, including eczema, atopic eczema, atopic 
dermatitis, childhood eczema, flexural eczema and prurigo Besnier (2). Controversy 
persists regarding the ideal nomenclature and definition (3). 
In 2004, the World Allergy Organization (WAO) published a consensus statement where 
eczema was divided into atopic eczema – for cases associated with immunoglobulin E (IgE) 
sensitisation to one or more common environmental allergens – and non-atopic eczema – 
for cases without such sensitisation (4). In this classification, specific IgE has to be detected 
through a positive skin prick test or in serum. However, this definition has not been 
generally adopted among dermatologists (5). Up to two thirds of patients with typical 
clinical manifestations of AD have no IgE-mediated sensitisation to common allergens (6). 
Moreover, IgE-associated AD and non-IgE-associated AD show substantial overlap and 
cannot be clinically separated from each other. Sometimes non-IgE-associated AD develops 
into IgE-associated AD, which complicates the WAO classification (7). 
Though the term eczema is the one most commonly used among patients and some doctors, 
it is highly unspecific (2). There are many different types of eczema and different 
underlying causes within the ‘eczema family’, e.g., seborrheic eczema, contact dermatitis 
(irritant or allergic) and nummular eczema (8). A recent meta-analysis showed that AD is 
the term most commonly used in scientific publications, and the authors suggested AD be 
the only term used, to achieve specificity and establish international agreement (2). In 
addition, AD is the Medical Subject Headings term used for indexing articles for PubMed. 
Hence, AD is the preferred term, regardless of IgE sensitisation. Therefore, it is used in this 
thesis. 
2.1.2 Clinical features 
Cardinal features of AD are generalised dry skin, recurrent eczematous lesions and pruritus, 
but clinical features have a wide spectrum (9). Symptoms can vary from minimal eczema to 
generalised erythroderma in severe cases. The word eczema is derived from the Greek word 
for ‘boiling out’ (1) and may reflect the oozing papulovesicles and erosions that can be seen 
in the acute phase of the disease. In contrast, chronic lesions usually have dry, scaly patches 
and plaques with lichenification and excoriations (9). Furthermore, clinical features can 
differ between ethnic groups. A follicular type with perifollicular accentuation and papules 
on the extensor surfaces of the extremities and on the trunk is more common in dark-
skinned individuals (10). The patterns of AD usually have an age-related clinical 
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appearance that can be classified into three phases (9, 11). The ‘infantile phase’ (up to 2 
years of life) generally involves the face, trunk and extensor surfaces of the limbs, whereas 
the napkin area is commonly spared. The ‘childhood phase’ (from age 1–2 years) typically 
involves the flexural folds in the elbows and knees, ankles, wrists and buttocks. The 
‘adolescent/adult phase’ (from approximately 12 years) usually has a similar distribution as 
in childhood, but frequently affects the face, head, neck and hands. Hand eczema may be 
the only manifestation in adults. Recently, a new subgroup of AD in age > 60 years has 
been described (12). In this group, the cubital and popliteal extensor areas are commonly 
involved, but the flexural areas tend to be spared (13). AD in the elderly has been observed 
to have a strong pruritic component and extensive erythematosus lesions up to 
erythroderma (12). There are many differential diagnoses in each age group. For example, 
among patients 16 years or older, cutaneous T-cell lymphoma is one of the diagnoses that 
should be excluded (14). Several other skin diseases sometimes resemble AD, including 
psoriasis, pityriasis rosea, pityriasis rubra pilaris and scabies. The possibility of allergic 
contact eczema should always be kept in mind (14). 
2.1.3 Diagnostic criteria 
Diagnosis may be a challenge, especially since no specific laboratory tests or histological 
findings have been identified (9). Several diagnostic criteria have been used to define AD, 
but few have been validated (15). The first widely used AD criteria were Hanifin’s and 
Rajka’s diagnostic criteria created in 1980 (15). These emphasise itch as a basic feature, 
with a comprehensive list of other features; a set number of major and minor features must 
be present for a diagnosis. These criteria are still sometimes used, but have been criticised 
as unrealistic for use in routine practice (15). The U.K. Working Party’s diagnostic criteria 
for AD, also known as Williams’s criteria, are a simplified and refined version of Hanifin’s 
and Rajka’s diagnostic criteria (Table 1) (16). These are the most well-validated and 
commonly used in clinical practice as well as in clinical trials and 
epidemiological/population-based studies (17). In a systematic review, the U.K. Working 
Party’s criteria showed a sensitivity of 10–100% and specificity of 89–99% (17). They have 
been validated in several different ethnic groups. The lowest sensitivity (10%) was found in 




Table 1. The U.K. Working Party’s diagnostic criteria for AD (1994). 
 
2.1.4 Epidemiology 
AD may be one of the most common chronic inflammatory diseases globally (18). Based 
on annual self-reported estimates, the prevalence is up to 20% among children and 10% 
among adults in high-income countries (14). Typically, AD has an early onset, with 60% of 
cases starting within the first year of life, but it can start in any age (9). Recent studies 
support that adult onset is more common than previously thought. A recent meta-analysis 
showed that 1 in 4 adults with AD reported adult onset (19). Some authors have questioned 
if this is ‘fact or fancy’ (20). One cannot exclude that participants had forgotten AD 
symptoms early in life and that persistence into adulthood might be a reflection of more 
severe cases (20). There are sparse and conflicting data regarding the long-term course of 
AD. Another recent meta-analysis of population-based cohorts of patients, followed 
longitudinally beyond childhood, suggested that outgrowing AD was less common than 
previously assumed (21). In a large Swedish hospital-based cohort of adult AD patients, 
followed up using questionnaires after 25–38 years, the majority of patients still reported 
the presence of AD (22). Nevertheless, in a Swedish general population-based study of 
children with preschool AD, half of the children were in complete remission by school age 
(from 4 through 16 years of age) (23).  
2.1.5 Pathophysiology  
The pathogenesis of AD is multifactorial and characterised by a complex interaction 
between epidermal barrier dysfunction and immune dysregulation (24, 25). Epidermal 
barrier dysfunction can be mediated through several factors, e.g., filaggrin gene (FLG) 
mutations – the most established cause of stratum corneum abnormalities – or by secondary 
mechanisms from itch-scratch and environmental exposures (9). The inflammatory 
response triggers epidermal disruption and itch, thus creating a vicious ‘itch-scratch cycle’ 
(18, 26). Much remains unknown regarding the mechanisms of chronic itch, but 
Must have:  
• An itchy skin condition (or parental report of scratching or rubbing in a child).  
 
Plus 3 or more of the following:  
• History of involvement of the skin creases such as folds of elbows, back of 
knees, fronts of ankles or around the neck (including cheeks in children under 10 
years).  
• A personal history of asthma or hay fever (or a history of atopic disease in a first-
degree relative in children under 4 years). 
• A history of generalized dry skin in the last year.  
• Visible flexural eczema (or eczema involving the cheeks/forehead and outer 
limbs in children under 4 years).  
• Onset under the age of 2 years (not used if the child is under 4 years).  
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psychological stress is one triggering factor among others (26). Skin barrier abnormalities 
have been observed in both eczematous lesions and non-lesioned skin in patients with AD, 
resulting in decreased skin hydration, increased skin pH, decreased sebum, and entry of 
allergens/irritants and infectious agents (18). 
AD is associated with a disordered microbiota, with a low bacterial diversity, which 
contributes to barrier dysfunction (14, 27). In normal skin, the bacterial microbiota 
produces inhibitors of Staphylococcus aureus, but in AD flares the altered skin microbiota 
allows proliferation of single strains of S. aureus (28). S. aureus expresses numerous 
virulence factors that contribute to the pathogenesis of AD. This involves release of toxins 
acting as T cell-activating ‘superantigens’, and proteases contributing to epidermal barrier 
damage (28). The reason for adherence of S. aureus to AD skin is unclear, but changes to 
the composition of the stratum corneum are likely to contribute (28). AD is also associated 
with colonisation of Malassezia yeasts, which have been observed to trigger AD, especially 
in a subset of AD patients with head-and-neck type AD (29). 
The effect of the inflammatory cascade is central in the pathogenesis of AD. The disrupted 
epidermal barrier, allergens, irritants and microbes stress keratinocytes to release 
proinflammatory and inflammatory cytokines. This activates dendritic epidermal cells, 
Langerhans cells and innate lymphoid cells (25, 30). The latter contribute to activation of 
Type 2 helper T (Th2) cells, which are considered to be key drivers of inflammation (25). 
Langerhans cells and dendritic cells pick up allergens and antigens that are presented to 
Th2 cells (25). The activated dendritic cells stimulate Th2 cells to secrete interleukin (IL)-4, 
IL-5, IL-13, IL-33 and IL-31 (30). The key inflammatory cytokines, IL-4 and IL-13, along 
with IL-5, activate the intracellular Janus kinase (JAK) and signal transducer and activator 
of transcription (STAT) pathway (31). Effects of this pathway include exaggeration of Th2 
response by increasing proinflammatory cytokines and downregulating antimicrobial 
peptides (31). It also promotes IgE class switching in B cells and eosinophil expression 
(14). IL-4 and IL-13 have been observed to reduce the expression of FLG and other 
proteins involved in the barrier function (25). IL-31 has been identified as an important 
mediator of pruritus, along with IL-4, IL-13, histamine and neuropeptides, through activity 
on sensory neurons (25). This completes the ‘itch-scratch cycle’. In the acute phase, the 
cutaneous cellular infiltrate in AD is characterised by Th2 and Th22 immune responses 
(25). It has been observed that Th1, Th22 and Th17 cells are activated and contribute to the 
pathology in chronic AD, for instance causing epidermal thickening and abnormal 
keratinocyte proliferation (30). Knowledge of the pathogenesis of AD is evolving rapidly. 
In summary: itch, barrier deficiencies, the microbiota and Th2-driven inflammation are 
currently considered to play important roles in AD.  
2.1.6 Genetics  
The strongest risk factor for AD is a family history of AD (14). This is supported by twin 
studies, where monozygotic twins are more often concordant for AD (72%) than dizygotic 
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twins (23%) (32). Several AD susceptibility genes have been identified through genetic 
studies. However, they explain less than 20% of the estimated heritability for AD (9). 
The strongest known genetic risk factor for AD is null mutation in FLG, which encodes the 
important epidermal structural protein filaggrin. Filaggrin facilitates the terminal 
differentiation of the epidermis, forming the skin barrier (33). Filaggrin-deficient skin is 
associated with increased skin surface pH, allergen penetration, decreased hydration of the 
stratum corneum and increased colonisation with Staphylococcus aureus (33). FLG 
mutations are well-known to be the underlying genetic cause of ichthyosis vulgaris, a skin 
disease characterised by dry scaling skin, palmar hyper-linearity and keratosis pilaris (18). 
These features are also associated with AD. In European populations, approximately 10% 
carry a single null FLG mutation and have a mild ichthyosis vulgaris and a three-fold 
increased risk of having AD (9). Although FLG mutations are a strong genetic factor, 
especially in severe cases, more than 50% of carriers never develop AD (18). This indicates 
that multiple, as-yet unknown, genetic factors are involved in the pathogenesis. Genetic 
studies of AD patients in Ethiopia show that FLG mutations are very rare compared with in 
European and Asian AD patients, suggesting that genetic causes of AD may vary between 
ethnic groups (34).	
2.1.7 Environmental risk factors 
The increased prevalence of AD over the last 50 years, especially in high-income 
communities and urban settings, has generated several hypotheses regarding environmental 
risk factors of AD (35). These include a ‘Western diet’ (high intake of refined grains, red 
meat, saturated and unsaturated fatty acids), broad-spectrum antibiotic exposure (repeated 
exposure before 5 years of age), living in an urban setting, low UV exposure or dry climate 
and small family size (35). A systematic review found that a higher prevalence of AD was 
associated with both active and passive smoking (36). However, it remains unclear if the 
disease burden of AD in terms of sleep disturbance and stress triggers smoking, or if 
smoking can directly aggravate AD (37, 38). 
In 1989, Strachan proposed the ‘hygiene hypothesis’. It implied that living in small families 
with improved household and personal hygiene led to an increased prevalence of allergic 
(atopic) disease by reducing the exposure to infections early in life (39). The hypothesis 
was supported by the recognition of the Th1 cytokine release pattern, induced by bacterial 
and virus exposure, which suppressed the Th2 response involved in IgE-mediated allergy 
(39). On the other hand, more recent epidemiological studies show that childhood 
infections (e.g., colds, measles) do not protect against allergic (atopic) disorders and there is 
no solid evidence that hygiene and cleanliness are the main cause of allergies (40). Some 
authors suggested that the hygiene hypothesis is ‘too clean to be true’ (41, 42), and 
increasing evidence supports the biodiversity hypothesis (41, 43). This suggests that non-
harmful microbes, acquired from the skin, gut and respiratory tract of other humans, and 
microorganisms from the natural environment may reduce the risk of immune 
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dysregulation. Thus, biodiversity loss related to an urbanised world may predispose to 
allergic and autoimmune disorders (44). 
2.1.8 The Harmonising Outcome Measures for Eczema initiative 
The Harmonising Outcome Measures for Eczema (HOME) initiative was established in 
2010 with the main purpose to standardise outcome measures that should be included in 
clinical AD trials (45). Before 2010, several AD treatments suffered a lack of high-quality 
evidence. This was partly due to the heterogeneity of outcome measures used in AD 
research and difficulties in comparing results between studies. HOME has identified four 
core outcome domains for AD: clinical signs, symptoms, quality of life and long-term 
control (46). The domains include specific validated and reliable outcome measures also 
feasible for the monitoring of patients in clinical practice. The outcome measures are valid 
until new studies refine or develop new scales (45). 
2.2 COMORBIDITY OF AD 
2.2.1 Atopic comorbidities 
WAO has stated the following: ‘Atopy is a personal and/or familial tendency, usually in 
childhood or adolescence, to become sensitised and produce IgE antibodies in response to 
ordinary exposures to allergens, usually proteins. As a consequence, these persons can 
develop typical symptoms of asthma, rhinoconjunctivitis, or eczema’ (4). AD is associated 
with and may predispose to other atopic comorbidities such as food allergy, asthma, allergic 
rhinitis, allergic conjunctivitis and eosinophilic esophagitis (47, 48). Food allergy, asthma 
and allergic rhinitis are the most common comorbidities (49). In a Swedish population-
based birth cohort, children with infantile AD had an increased risk of both rhinitis (OR 
2.69; 95% CI, 2.22–3.26) and asthma (OR 2.22; 95% CI, 1.65–2.98) in pre-adolescence 
(50). Approximately one third of children with moderate-to-severe AD, and up to 10% of 
the adult population with AD, suffer from food allergy (18). Cow’s milk, hen’s egg, peanut, 
wheat, soy, nuts, and fish are responsible for more than 90% of food allergies in children 
with AD, where milk and egg allergy are the most frequent (51). Milk allergy usually 
resolves before the age of about three years (52). Resolution of egg allergy has been 
reported for more than half (68%) of 16-year-olds (52). 
In general, the clinical signs of AD start before the development of food allergy, asthma 
and allergic rhinitis, which then follow in a progressive order (49). AD and food allergy 
usually dominate in early childhood, while asthma and rhinitis may persist into adulthood. 
This concept of an age-associated development of atopic diseases is historically referred to 
as the ‘atopic march’ and implies that AD is required for the development of IgE 
sensitisation, leading to other disorders (49). However, many patients develop atopic 
disorders without the occurrence of AD, and IgE-mediated sensitisation does not seem to be 
the major mechanism for driving atopic comorbidities (18). Recent studies suggest that 
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shared genetic loci and environmental triggers contribute to a clustering of atopic disorders, 
but not always in a progressive ‘march’ (49). 
2.2.2 Non-atopic comorbidities 
Associations between AD and non-atopic comorbidities, such as certain cancers, 
cardiovascular, autoimmune, infectious and neuropsychiatric disorders have been reported 
increasingly often, but the relationships of these conditions with AD are not fully 
understood (47, 53). Some authors conclude that the associations between AD and non-
atopic comorbidities are most likely multifactorial, involving systemic low-grade 
inflammation, environmental exposure, genetic predispositions, medication, lifestyle and 
behavioural risk factors (37). Comorbidities could also be secondary to the burdensome 
symptoms of AD (47). Itch and pain may have a severe negative impact on health-related 
quality of life (HRQoL) due to disturbed sleep, as well as having a negative influence on 
emotions, socio-economy and daily activities (54). 
2.2.3 Cardiovascular disease 
In recent years, a number of epidemiological studies have explored the association between 
AD and CVD (53). A Danish cohort study found an association between severe AD and 
cardiovascular death, but the result did not remain after adjustment for socioeconomic 
status, smoking, comorbidities and medication use (55). The same team also conducted a 
systematic review and meta-analysis and did not find any association between AD and 
hypertension, diabetes mellitus type 2 (DM2), myocardial infarction (MI) or stroke (56). In 
contrast, a recent large population-based study from the United Kingdom found that severe 
AD had a higher risk of CVD and stroke, which remained in adjusted models for well-
established cardiovascular risk factors (57). A meta-analysis, including studies up to 2017, 
found no overall association between AD and CVD, but did find an association between 
increasing AD severity and CVD. The researchers concluded that significant associations 
between AD and CVD were more common in cohort studies, while the effects of AD in 
cross-sectional studies were heterogeneous (58). In summary, epidemiological studies have 
shown conflicting results. 
2.2.3.1 Hypotheses on a relationship between AD and cardiovascular disease  
There are several hypotheses on a potential causal relationship between AD and CVD (37, 
59, 60). The relationship may be influenced or explained by a number of mediators and 




Figure 1. A model of a potential causal relationships between AD and cardiovascular 
disease. Potential factors considered possible as both mediators and confounders marked 
with *. 
It has been suggested that an important mechanism for arteriosclerosis among AD patients 
is mediated by chronic systemic inflammation, in line with the observed risks among 
patients with psoriasis (61). An increase of cardiovascular risk proteins, including markers 
of Th1 (i.e., interferon gamma (INF-γ) and tumour necrosis factor (TNF)-β/lymphotoxin) 
and Th17 immune responses, has been observed in both chronic AD and psoriasis (62). 
However, the overall blood signatures differed in AD and psoriasis. AD has been associated 
with several cardiovascular risk factors such as smoking (36). Large population-based 
studies in the US found that AD patients had an association with sedentary lifestyle and 
alcohol consumption (47). A meta-analysis found an association between obesity and 
increased prevalence and severity of AD (63). However, in a sensitivity analysis, the 
association between AD and obesity was significant only in North American and Asian 
populations, not in European populations. Additionally, AD has been associated with 
multiple comorbidities (hypertension, DM2 and hyperlipidaemia) that are well-known 
cardiovascular risk factors (64, 65). It has been discussed if glucocorticoids may be a 
mediating factor between AD and CVD (59). The use of long-term systemic 
glucocorticoids has for various diseases been linked to adverse events including 
hypertension, DM2 and obesity (66). A recent systematic review found an association 
between use of topical glucocorticoids and development of DM2 (67). A cohort study 
found that exposure to > 7.5 mg of prednisolone per day for 1–5 years was associated with 
CVD (68). Nevertheless, long-term use of oral glucocorticoids is not among the 
recommendations for AD treatment in international guidelines (38).  
Sleep disturbances have been associated with increased morbidity and mortality in CVD, 
regardless of their underlying cause (69). Several explanations have been suggested, 
including involvement of the autonomic nervous system, inflammation and the coagulation 
system. This is relevant as sleep disturbance is one of the major subjective symptoms of 
AD. Eczema among U.S. adults – which, however, cannot be equated with AD – has been 
associated with more than doubled odds of sleep disturbance, fatigue and regular daytime 
sleepiness compared with in healthy controls (70). The authors linked difficulties falling 
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asleep and premature awakening to itch. Another study, including adults with AD from 
several countries, found that an average of 8.4 nights had disrupted sleep during a typical 
AD flare (71), which could be extrapolated to at least 81 days per year and patient (70). 
Lastly, several studies have shown an association between depression and CVD. 
Depression has also been suggested as a causal risk factor for CVD (72), or as the saying 
goes, ‘can break your heart’. 
2.2.4 Autoimmune disease 
Increasing evidence suggests an association between AD and several autoimmune 
conditions, including Crohn’s disease, ulcerative colitis, coeliac disease, alopecia areata and 
vitiligo (64, 73). A recent systematic review found that autoimmune diseases involving skin 
and intestinal mucosa were more frequent in patients with AD, including systemic lupus 
erythematosus, while the correlations to diabetes mellitus type 1 (DM1), autoimmune 
thyroiditis and rheumatoid arthritis (RA) showed conflicting results and data on several 
major autoimmune diagnosis were limited (74). The underlying pathogenic mechanisms 
relating autoimmunity to AD remain unclear; some theories are presented below. 
2.2.4.1 Hypotheses on a relationship between AD and autoimmune disease 
Patients with moderate-to-severe AD has been observed to higher serum levels of 
proinflammatory markers, including IL-7, compared with controls (75). This may support 
AD as a systemic disorder and enhanced bioactivity in the IL-7 axis has been linked to a 
higher risk of DM1, RA and multiple sclerosis (MS) (75). Moreover, several studies have 
observed an increased risk of AD in patients with alopecia areata (76), and FLG mutations 
seem to be a strong risk factor for a severe course of alopecia areata, indicating genetic 
linkage (64, 77). Overlap between genetic loci in AD and other immune-mediated diseases, 
e.g., psoriasis and inflammatory bowel disease, has been shown, but environmental triggers 
are also shared, such as smoking and socioeconomic status (36, 53). Moreover, AD patients 
are more likely to present with multiple autoimmune comorbidities, supporting the idea of 
an autoimmune component of AD (78). Several studies indicate an association between AD 
and increased prevalence of anti-nuclear antibodies and/or IgE autoantibodies (i.e., immune 
response to autologous tissue, cells or proteins (78)). The latter could contribute to 
progression of AD and has been linked to AD disease severity. 
2.2.5 Depression 
The association between AD and depression and suicidal ideation is well-established (79, 
80). The association has been observed to be stronger among patients with moderate-to-
severe AD, although data are conflicting (79). Data on the magnitude of depression among 
patients with moderate-to-severe AD are scarce. 
Very few studies have explored the effect of systemic AD treatment on depression 
symptoms. A Japanese study found that ‘tight control’ of AD with oral ciclosporin and 
topical glucocorticoids reduced depression symptoms (80). In clinical trials, dupilumab 
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reduced depressive symptoms (81), but whether this holds true when treatment is delivered 
within routine dermatological care is unknown. 
2.2.5.1 Hypotheses n a relationship between AD and depression 
Several symptoms of AD, such as itch and sleep disturbance, have been linked to AD 
severity (82). Insomnia is a well-recognised independent risk factor for development of 
depression, and one of the cardinal symptoms of a major depressive disorder (83). Further, 
the burden of disease extends beyond physical symptoms. Several factors have been 
assumed to cause depression among patients with AD, such as social isolation, 
stigmatisation due to facial eczema, restrictions in occupation and sports activities, 
problems in relationship and with sexuality, and financial costs (47, 84). AD patients have 
also been observed to have an alteration in their proinflammatory cytokine levels related to 
the metabolism of neurotransmitters including serotonin, norepinephrine and dopamine 
(85). Thus, it is possible that chronic neuroinflammation in AD may contribute to 
depression (86). 
2.3 SYSTEMIC TREATMENT OF AD 
2.3.1 Overview of AD management  
At present, there is no therapeutic cure for AD. The aim of AD management is to reduce 
pruritus, improve HRQoL and establish long-term disease control (38). Cornerstones of 
basic treatment comprise avoidance of trigger factors, continuous use of emollients to 
restore the epidermal barrier, and topical anti-inflammatory therapy (glucocorticoids, 
calcineurin inhibitors) (9). Additionally, patient education of AD involving disease 
management and strategies to cope with the disease are important to improve HRQoL and 
eczema severity (87). Basic therapy is sufficient in most AD cases and is included in 
maintenance therapy for all AD patients. However, such interventions and phototherapy 
(UVB) often have limited efficacy in moderate-to-severe AD. Adults with severe AD have 
for many years been treated with conventional systemic drugs, such as ciclosporin, 
methotrexate, azathioprine and mycophenolate mofetil (14). Only ciclosporin is approved 
for AD; the others are used off-label (14). Long-term management with systemic 
glucocorticoids is not recommended due to the risk profile, and though shorter courses are 
common, they may cause flares (88). AD can be challenging to treat, and off-label systemic 
treatments may be contraindicated, ineffective or induce adverse events. Improved 
understanding of the immunopathogenesis of AD has led to a new era in development of 
systemic treatments that are more specific for certain targets, such as type 2 immunity, 
JAK-STAT and itch signalling pathways (18). In 2017, dupilumab, the first biologic for 
AD, was approved in Europe for patients with moderate-to-severe disease (31). Baricitinib, 
a selective inhibitor of JAK1 and JAK2, has recently been approved in Europe with the 
same indication (89). Several new treatments for AD may be introduced in the near future. 
The following section discusses the most commonly used systemic treatments, including 
the two recently approved drugs. 
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2.3.2 Conventional systemic drugs for AD 
2.3.2.1 Ciclosporin 
Ciclosporin, acting through inhibition of T cell proliferation, is currently the recommended 
first-line short-term treatment for moderate-to-severe AD in several European countries 
(90, 91). Multiple clinical trials have shown significant rapid effect within 2–6 weeks (often 
around 2 weeks), but prompt relapse of clinical and subjective symptoms of AD is common 
if the medication is stopped (88, 90). The most common adverse events include nephrotoxic 
effects and hypertension, especially with doses exceeding 5 mg/kg/day and among elderly 
patients. The treatment period is recommended not to exceed 2 years, although many 
patients have been observed to tolerate low doses for longer periods of time (92). 
2.3.2.2 Methotrexate 
Methotrexate (MTX), a folic acid antagonist thought to suppress several T cell activities, 
has been used for more than 50 years as an immunosuppressant for various dermatological 
diseases (93). Despite its long history in dermatology, very few published studies have 
explored the effects and adverse events of MTX for AD. Nevertheless, in clinical practice, 
it has been reported to yield a good clinical response (90). A randomised trial including 42 
patients compared MTX with azathioprine (94). At week 12, both treatments were 
considered to achieve clinically relevant improvement and to be safe for short-term use. 
The average time to response has been estimated to 8–12 weeks (90). The most severe side 
effects reported include bone marrow suppression, hepatotoxicity and pulmonary fibrosis. 
Therefore, folic acid supplementation is recommended to reduce the risk of hematologic 
and gastrointestinal toxicity (88). 
2.3.2.3 Azathioprine 
Azathioprine, a purine analogue that is converted into 6-mercaptopurine (6-MP), acts by 
inhibiting DNA production, especially in cells with a high proliferation rate, such as B and 
T cells (95). Studies on efficacy and long-term safety are limited. For short-term use, it is 
considered to be an effective treatment – comparable with methotrexate – although one 
study concluded that adverse events were common (90). The most common adverse events 
included headache, gastrointestinal symptoms, elevated liver enzymes and bone marrow 
toxicity (88). During metabolism of azathioprine, thiopurine methyltransferase inactivates 
6-MP. Consequently, among patients with thiopurine methyltransferase deficiency 
(approximately 10% of the general population), there is a risk of azathioprine toxicity even 
at subtherapeutic doses (95). Therefore, measurement of this enzyme is strongly 
recommended before initiating treatment, especially to reduce the risk of severe bone 
marrow suppression (95). 
2.3.2.4 Mycophenolate mofetil 
Mycophenolate mofetil is an immunosuppressant inhibiting B cell and T cell proliferation 
(88). Some case reports and clinical data indicate that mycophenolate mofetil may be 
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effective in AD and it is generally well-tolerated. Gastrointestinal problems are the most 
common side effects (90). Other observed adverse events include bone marrow suppression 
and infections. Data supporting the use of mycophenolate mofetil in AD are limited, and 
therefore it has only been recommended (off-label) if ciclosporin has failed or is not 
indicated (90). 
2.3.3 Novel systemic drugs for AD 
2.3.3.1 Dupilumab 
Dupilumab is a human monoclonal antibody that inhibits IL-4 and IL-13 signalling through 
blockade of the shared IL-4α subunit (96). By blocking IL-4/IL-13 signalling, dupilumab 
effectively suppresses T helper 2-mediated inflammation and restores the skin barrier 
function (96). The effect is mediated through downregulation of receptor signalling 
downstream of the JAK-STAT pathway, which regulates many genes involved in the 
pathogenesis of AD (97). Dupilumab has been shown to result in significant improvement 
in clinical parameters and has a good safety profile. Looking at all trials published up to 
2018, around 70% of the patients achieved a 75% improvement from baseline (EASI-75) 
during the study periods, and full clinical response was observed around week 4 (90). 
Approximately 15% more patients achieved EASI-75 at week 16 when dupilumab was 
evaluated with concomitant topical glucocorticoids (96). In 2018, a meta-analysis of 
adverse events in clinical trials found that dupilumab slightly increased the risk of headache 
and moderately increased the risk of injection site reactions compared with placebo, and 
conjunctivitis was observed in 8% of participants (98). In 2021, a systematic review and 
meta-analysis of real-world data found that dupilumab was effective and well-tolerated. 
The mean reduction in EASI score at week 16 was comparable with that in clinical trials. 
Ocular adverse events were the most common side effect and the main reason for treatment 
discontinuation (99). 
2.3.3.2 Baricitinib 
Baricitinib is an oral selective JAK1 and JAK2 inhibitor. Two independent phase III trials 
reported that baricitinib in monotherapy for moderate-to-severe AD improved clinical signs 
and symptoms, and that itch was improved within one week (100). The effect appeared to 
be inferior to that of dupilumab at 16 weeks’ follow-up, but advantages may include rapid 
effect on itch, oral administration and a different profile of adverse events that may be 
better for some patients. Upper respiratory tract infections, creatine phosphokinase 
elevations and headache were the most common side effects. In pooled analyses of 8 
randomised clinical trials, the most common serious adverse events were eczema 




3 RESEARCH AIMS 
The overall aims of the thesis were to increase knowledge on the association between AD 
and non-atopic comorbidities, and on the efficacy and adverse events of current and new 
systemic treatment for AD. The included research projects aimed more specifically to: 
1. Investigate the association between AD and CVD, i.e., coronary artery diseases 
(CAD; angina pectoris and MI) or ischaemic stroke. 
2. Investigate the association between AD and autoimmune diseases. 
3. Describe ocular adverse events and weight gain from dupilumab treatment for AD 
in adults. 
4. Describe depressive symptoms in adults with AD before and during systemic 
treatment.   
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3.1 RESEARCH FRAMEWORK 






Research questions Methodological 
approach 
Study/Outcome 
Comorbidity  What is the association 
between AD and 
coronary artery disease 
and/or ischaemic 
stroke? Does the 
magnitude of such 
associations vary with the 





I. Coronary artery 
disease and/or 
ischaemic stroke 
What is the association 
between AD and 
autoimmune diseases? 
 
II. Autoimmune disease 
 
 











What ocular adverse 
events are associated with 
systemic treatment of 
AD? 
 
III. Ocular adverse 
events 
 
Is dupilumab treatment of 
AD associated with 
weight gain? 
 
IV. Weight gain 
How does systemic 







4 MATERIALS AND METHODS 
4.1 A SUMMARY OF THE MATERIALS AND METHODS IN THE THESIS 
Table 3. A summary of the studies included in the thesis. 
Study I II III/IV V 















age ≥ 15 years, 
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Data source The National 
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the Medical Birth 
Register, the Cause 
of Death Register, 
the Swedish 
Prescribed Drug 
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AD: Atopic dermatitis. *The Longitudinal Integration Database for Health Insurance and 
Labour Market Studies. **Study III: Treated with dupilumab ≥ 3 months, Study IV: 
Treated with dupilumab and/or methotrexate ≥ 6 months. ***National Swedish quality 
register for Atopic Dermatitis (SwedAD) a Friedman’s repeated measurements analysis of 
variance (ANOVA).  
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4.2 DATA SOURCES 
4.2.1 National registers 
The history of the Swedish national population registers goes back to the 17th century. The 
Swedish church registers enabled the Swedish state to enrol soldiers for the army and to 
collect taxes (102). Today, the primary aim of the national registers, held by Statistics 
Sweden (SCB) and the National Board of Health and Welfare (NBHW), is to provide 
complete population-based data to the government and to facilitate analyses and decisions. 
Swedish register data have also been, and still are, an important part of Swedish medical 
and epidemiological research. Personal identity numbers enable linkage of data from 
several Swedish national and health care registers. The national registers below were used 
as data sources for the epidemiological studies in this thesis. 
4.2.1.1 The National Patient Register 
The National Patient Register (NPR) comprises data about inpatient diagnoses and hospital 
discharges from 1964 onward (the Swedish National Inpatient Register) and has complete 
national coverage since 1987. Additionally, the NPR holds the outpatient register with data 
from both private and public caregivers since 2001 (103). The NPR is maintained by the 
NBHW. 
Diagnoses are coded based on the Swedish International Classification of Disease system 
(ICD). The coverage of inpatient diagnoses is almost 100% for all somatic (including 
surgery treatments) and psychiatric diagnoses. The coverage of outpatients is lower (about 
80%), mainly because of missing data from private caregivers. Validation of the Swedish 
national inpatient register has shown a positive predictive value of about 85–95% for most 
diagnoses (103). The validity of the correctness of AD has, to my knowledge, not yet been 
investigated. 
4.2.1.2 The Medical Birth Register 
The Swedish Medical Birth Register, held by the NBHW, has information about all births 
in Sweden since 1973 (104). It contains information about pregnancy, delivery and the 
new-born child. Additionally, it includes detailed data of mothers registered in prenatal 
care, such as pre-existing diagnoses, maternal drug use, smoking habits and weight (105). 
Data on smoking are available from the Medical Birth Register for women registered in 
antenatal care after 1982. 
4.2.1.3 The Cause of Death Register  
The Swedish Cause of Death Register is one of the oldest in the world (106). The Swedish 
parliament introduced a nationwide reporting system for cause of death statistics in 1749. 
However, for more than a century, only ‘important’ causes of deaths were recorded, such as 
maternal death and death in an epidemic. The Cause of Death Register has full coverage 
since 1952, including data on cause and date of death. It also includes data on Swedish 
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residents who died abroad. The completeness of the register is almost 100% and 96% of 
individuals in the register have a specific underlying cause of death recorded. The quality of 
the register is closely linked to that of death certificates and therefore most reliable for 
those who died in hospitals. High agreement between medical records and the Cause of 
Death Register has been reported for several diseases, including death from cardiovascular 
disease (106). The Cause of Death Register is maintained by the NBHW. 
4.2.1.4 The Swedish Prescribed Drug Register  
The Swedish Prescribed Drug Register, held by the NBHW, contains information about all 
prescribed drugs dispensed at Swedish pharmacies since July 2005 (107). It includes the 
personal identity number of the patient, the prescriber’s profession, speciality and 
workplace address. It has detailed information about the dispensed item (Anatomical 
Therapeutic Chemical [ATC] code, date of prescription, dispensing, dosage and brand 
name). The register does not include over-the-counter drugs and drugs used for inpatients in 
hospitals. It only includes some of the drugs used in outpatient care, which may be 
administrated in hospital day care; examples include intravenous infusions. 
4.2.1.5 The Total Population Register 
The Total Population Register, maintained by SCB, was established in 1968 and is since 
then updated with new data every year. It contains data on births, deaths, 
immigration/emigration, civil status and place of residence of the population alive at the 
end of the year (102). 
4.2.1.6 The Longitudinal Integration Database for Health Insurance and Labour Market 
Studies 
The Longitudinal Integration Database for Health Insurance and Labour Market Studies 
(LISA), maintained by SCB, holds information on employment, income and education for 
the Swedish population 16 years or older (108). 
4.2.1.7 The Multi Generation Register 
The Multi Generation Register, maintained by SCB, contains links to biological parents. 
Persons who have been registered in Sweden at any time after 1961 and who were born 
1932 or later have a link to their own parents and their own biological children (109). It 
also holds information about adoptive parents.  
4.2.2 The Swedish quality register for atopic dermatitis (SwedAD) 
In 2017, the research group with which I was associated during my thesis project launched 
a database and quality register for patients on systemic treatment for AD (system platform 
DermaReg provided by Carmona, Halmstad, Sweden). The purpose was to follow up the 
effects and adverse events of current and new treatments for AD using established scoring 
systems and systematically and prospectively collected information. The establishment of 
 
24 
the quality register, SwedAD (Figure 2) (110), has been an important part of my thesis 
work and was a prerequisite for Studies III–V. 
The register includes, among other things, detailed demographic data, information about 
working limitations due to eczema, information about atopic and non-atopic comorbidities, 
information about smoking and alcohol consumption, laboratory values, including FLG 
mutations and IgE sensitisation, information about contact allergies, data on duration of 
pharmacotherapy and adverse events from systemic treatment for AD. Patient-reported data 
are collected via tablets or mobile phones at each patient visit and investigator-reported data 
are entered through a computer. The platform has data from the Karolinska University 
Hospital from January 10, 2017 and was launched for national use on September 1, 2019, in 
dialogue with the ‘Svenska Sällskapet för Dermatologi och Venereologi’ and the 
‘Nationella programområdet (NPO) för dermatologi och venereologi’. 
 
Figure 2. The logo of National Swedish quality register for Atopic Dermatitis (SwedAD). 
4.2.2.1 Outcome measures 
SwedAD includes outcome measures recommended by HOME. Additionally, SwedAD has 
information about depressive symptoms and other variables, as previously outlined. 
Outcome measures for long-term disease control are not yet included, but will be 
considered in the future. 
The Eczema Area and Severity Index (EASI) is the core outcome measure of clinician-
reported signs of AD at a clinical examination of the patient and measures erythema, 
excoriations, oedema/papulation and lichenification (46). The signs and extent of disease 
are weighted equally. The EASI score ranges from 0 to 72, with higher scores indicating 
greater severity of AD. The minimal clinically important difference for change in EASI 
score between two examinations has been estimated to 6.6 (111). Change in EASI scores 
may also be presented as improvement from baseline by 50%, 75% or 90% (46), in this 
thesis referred to as EASI-50, EASI-75 and EASI-90, respectively. 
The Patient-Oriented Eczema Measure (POEM) measures patient-reported symptoms of 
AD in the past 7 days (112). It captures the frequency of seven symptoms, including itch, 
sleep disturbance, bleeding, weeping or oozing, cracking, flaking and dryness. The POEM 
score ranges from 0 to 28, where a higher score indicates a greater symptom burden of AD. 
POEM does not capture the intensity of these symptoms. An improvement by 4 points is 
considered to be the minimal clinically important difference for change (111). 
SwedADSvenskt kvalitetsregister för atopisk dermatit
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The Peak Pruritus Numerical Rating Scale (NRS-11) measures the worst peak itch over 
the last 24 hours reported by the patient (113). The scale has 11 steps, ranging from 0 to 10, 
with 10 being the “worst itch imaginable”. A recent validation study has suggested that a 
change of more than 2–4 points from baseline is clinically relevant (113). Only a few 
instruments are validated to estimate itch severity over the last 24 h among adults. High 
reliability and validity has been found between a visual analogue scale (VAS) for the last 
24 h (100 mm line) and NRS-11 (114), but VAS has limited evidence for construct validity 
and was therefore not recommended in the HOME consensus meeting in 2019 (115). VAS 
for pruritus during the last 3 days was used by SwedAD until September 2019, thereafter 
being replaced by NRS-11, as recommended by HOME. 
The Dermatology Life Quality Index (DLQI) is a self-report questionnaire to evaluate 
skin disease impact on HRQoL (116). The scale ranges from 0 to 30, with higher scores 
indicating greater effect on HRQoL. The questionnaire domains include symptoms and 
feelings, daily activities, leisure, work/school, personal relationships and treatment. 
The Montgomery Åsberg Depression Rating Scale-Self-report (MADRS-S) is a self-
rated questionnaire to evaluate depression and change of depressive symptoms (117, 118). 
The MADRS-S includes nine questions related to reported sadness, feelings of unease, 
reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, 
pessimism and suicidal thoughts (119). Each of these items may score between 0 and 6, and 
thus the sum can range between 0 and 54 points, with higher scores indicating a more 
severe depression. The threshold scores for different levels of depression vary between 
studies. The cut-off scores recommended by Svanborg and Ekselius, including the score for 
severe depression recommended by Snaith et al., are commonly used in Swedish studies. 
No depression is defined as 0–12, light depression as 13–19, moderate depression as 20–34 
and severe depression as ≥ 35 points (120-122). In Study V, item 9 in MADRS-S was used 
to assess suicidal thoughts. For that item, 0 means ‘enjoys life or takes it as it comes’ and 6 
means ‘explicit plans for suicide when there is an opportunity’. Exhibiting marked suicidal 




4.3 STUDY DESIGN AND STUDY POPULATION 
4.3.1 Register-based case-control studies: Studies I–II 
In Studies I–II, nationwide register-based case-control studies were conducted to 
investigate the association between AD and comorbidities as presented in Tables 4–6. Data 
were linked from several Swedish national registers. The source population comprised the 
entire Swedish population aged 15 years or older in the years 1968 through 2016. All 
patients with an inpatient diagnosis of AD (from 1968 onward) or an outpatient diagnosis 
of AD (from 2001 through 2016) were identified in the NPR and treated as cases. For 
comparison, 10 randomly selected age- and sex-matched control subjects for each case 
were identified from the Total Population Register. Exclusion criteria were reused personal 
identity numbers, incomplete records and lack of matching controls. Controls with an AD 
diagnosis before the age of 15 years were excluded. The final study population included 
104,832 cases with AD and 1,022,435 controls. The AD diagnosis and comorbidities were 
identified from the NPR and from the Swedish Death Register using ICD codes (Tables 4–
5). 
Table 4. International Classification of Disease (ICD) codes used to identify atopic 
dermatitis. 
 ICD-8 ICD-9 ICD-10 
Atopic 
dermatitis 
691.00 691 L20.0–L20.9 
 
 
Table 5. International Classification of Disease (ICD) codes used to identify comorbidity of 
cardiovascular disease. 
 ICD-8 ICD-9 ICD-10 
Diabetes mellitus 250 250 E10, E11, E12, E13, E14 
Hypertension      400, 401, 402, 403, 404 401, 402, 403, 404, 405 I10, I11, I12, I13, I15 
Hyperlipidaemia 272 272 E78   
Angina pectoris 413 411B, 413 I20 (I20.0, I20.1, I20.8, I20.9) 
Myocardial 
infarction 
410 410 I21, I22 






Table 6. International Classification of Disease (ICD) codes used to identify autoimmune 
diseases. 
Group/Name*  ICD-10 ICD-9 ICD-8 





 Dermatomyositis M330/M331/ 
M339 
710D 716.0 
 Polymyositis M332 710E 716.1 
 Rheumatoid arthritis M05 714 712.0–3/712.5 
 Systemic scleroderma M34 710B 734.00 
 Systemic lupus erythema-
tosus 
M32 710A 734.1 
Dermatologic Alopecia areata L63 704A*** 704.00 
 Chronic urticaria L508 708W 708.91 
 Dermatitis herpetiformis L130 694A 693.99 
 Pemphigoid/pemphigusa L12/L10 694F/694E 694 
 Psoriasis L40 696A,B 696.0–1 
 Vitiligo L80 ** 709.05 
Digestive Coeliac disease K900 579A 269.0 
 Crohn’s disease K50 555 563.0 
 Ulcerative colitis K51 556 563.1 
Endocrine Addison’s disease E271 255E 255.1 
 Diabetes mellitus type 1 E10 ** ** 
 Graves’ disease E05 242 242 
 Hashimoto’s disease E063 245C  
Haematologic Antiphospholipid syndrome D686A   
 Autoimmune haemolytic 
anaemia 
D591 283A  
 Pernicious anaemia D510 281A 281.0 
Hepatic Autoimmune hepatitis K754   
 Primary biliary cholangitisb K743 571G  
Neuromuscular Guillain-Barré syndrome G610 357  
 Multiple sclerosis G35 340 340 
 Myasthenia gravis G700 358 733 
Vascular Granulomatosis with 
polyangiitisc 
M313 446E 446.2 
 Polymyalgia rheumatica M353 725 446.38 
 Temporal arteritis M315 446F 446.30 
*Coded according to ICD-8: 1968–1986, ICD-9: 1987–1996, and ICD-10 thereafter. **Not 
included due to wide definition. ***Alopecia, including alopecia areata. a Historically, in 
ICD-8, the same ICD code was used for pemphigus and pemphigoid and they were therefore 
seen as a group in the overall analysis of disease association. When investigating the age of 
onset for pemphigus and pemphigoid, we analysed these diagnoses separately and restricted 
the analyses to ICD-9 and ICD-10 codes. b Previously known as primary biliary cirrhosis.  
c Previously known as Wegener’s granulomatosis. 
4.3.1.1 Study I 
The research question addressed the association between AD and comorbidity with CVD, 
i.e., CAD and/or ischaemic stroke, comparing AD patients with controls and further 
explored if the magnitude of any such association varied with the severity of AD or with 
sex. Patients were classified as having severe AD if they were prescribed systemic 
treatment for AD (MTX, azathioprine, ciclosporin, and/or mycophenolate mofetil) or if 
they had been treated at a dermatological ward with AD as their main diagnosis. Otherwise, 
AD was classified as non-severe. Information on dispensed drugs was obtained from the 
Swedish Prescribed Drug Register. 
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Covariates: The highest attained level of education, obtained from LISA, was included as a 
proxy for socioeconomic status. Multivariable analyses further included cardiovascular 
comorbidity defined as DM1 or DM2, hyperlipidaemia and hypertension. The influence on 
CVD of smoking and body mass index (BMI), respectively, was examined in a 
subpopulation of women, using mothers registered in antenatal care between 1982 and 
2016. Information about mothers was obtained from the Medical Birth Register. 
4.3.1.2 Study II 
This study explored the association of AD with multiple autoimmune diseases separately, 
but also with an organ system-based approach and with respect to sex. 
Covariates: Multivariable models included education. In a sub-analysis, further adjustment 
was made for any parental autoimmune disease, but also for specific autoimmune diseases 
shared between parent and offspring. Information about heredity was obtained by linkage to 
the Swedish Multi-Generation Register. In sub-analyses of women, smoking was included 
in multivariable analyses as described in Study 1. 
4.3.2 Clinical observational studies: Studies III–V 
In the prospective clinical cohort studies, the overall aim was to study certain adverse 
events from dupilumab. An additional aim was to examine the prevalence of depression 
among patients with moderate-to-severe AD, and the effects of systemic treatment of AD 
(MTX, ciclosporin or dupilumab) on depressive symptoms. The patients started with a 
loading dose of 600 mg dupilumab injected subcutaneously, followed by 300 mg every 
other week. The dosage of other systemic drugs followed European dosing guidelines from 
2018 (90). Patients who started on dupilumab had a wash-out period of at least two weeks 
for any previous systemic treatment. All patients in Studies III–V were on topical 
maintenance therapy. Outcome measures included scores on EASI, POEM, DLQI, 
VAS/NRS-11 and MADRS-S. These were monitored at baseline and every 3–6 months 
thereafter. Most of the patients were also monitored after 1 month. 
The inclusion criteria were as follows: (1) age ≥ 18 years, (2) diagnosed with AD according 
to the U.K. Working Party’s diagnostic criteria, (3) treated at the Department of 
Dermatology, Karolinska University Hospital, and (4) registered in the local research 
register/SwedAD. Additional inclusion criteria in Studies IV–V are described below.  
4.3.2.1 Study III 
In this case-series, ocular adverse events among AD patients treated with dupilumab 
(Dupixent®, Sanofi-Aventis Groupe, Paris, France) between November 2017 and June 
2018 were recorded. At baseline, the patients were prescribed daily use of a Vaseline 
ointment (Oculentum simplex®) as a preventive measure against conjunctivitis. 
Assessment of ocular adverse events were diagnosed and treated by an ophthalmologist. 
Dupilumab had not previously been used at the department in question. 
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Study population: A total of 10 patients (1 woman, 9 men; age range 23–59 years) with 
severe AD were included. All patients had used systemic treatment for AD on and off for at 
least 4 years prior to initiation of dupilumab. All had a history of asthma and/or allergic 
rhinoconjunctivitis and three had FLG mutations. Half of the patients had a previous history 
of eye disease (conjunctivitis, blepharitis, herpes uveitis, keratoconus, bacterial keratitis 
and/or iridocyclitis). 
4.3.2.2 Study IV 
This cohort study investigated weight change during systemic treatment of AD from 
baseline to the 12-month follow-up. The associations between weight change and treatment 
response were explored, as well as reported appetite and/or disturbed sleep due to itching. 
The aim was to characterise these associations by comparing treatment groups (MTX vs. 
dupilumab). Reduced appetite was assessed with question number 4 in MADRS-S, where 
higher scores indicate less appetite. Disturbed night sleep due to itching was assessed with 
question number 2 in POEM, where higher scores indicate more severe sleep disturbance. 
Additional inclusion criteria: (1) initiation of treatment with dupilumab and/or MTX 
between January 10, 2017 and June 30, 2019, (2) complete records on weight at the 6-
month follow-up or later. 
Study population: In total, 41 patients had treatment initiated within the study period, but 
many were excluded from the final analyses because of short follow-up periods (n = 15) 
and/or missing weight data (n = 8). The final cohort consisted of 12 patients with 
dupilumab and 8 patients with MTX treatment. Two patients had follow-up data for both 
MTX and dupilumab and were included in both treatment groups. The primary endpoint 
was weight change at the 12-month follow-up. Five patients had missing values at this 
timepoint and weight data from either the 6-month (n = 3) or the 9-month (n = 2) follow-up 
were used instead. 
4.3.2.3 Study V 
This cohort study comprised two parts. First, it explored the prevalence of depression and 
suicidal ideation among AD patients eligible for systemic treatment of AD. The primary 
outcome measure was MADRS-S score. Second, it evaluated the efficacy of systemic AD 
treatment on depressive symptoms and the correlation between MADRS-S scores and 
scores on EASI, POEM, DLQI, or VAS/NRS-11. Baseline data were analysed at start of the 
first treatment registered (within 4 weeks before start and up to 2 weeks after start). Follow-
up data at 6 months (range 3–9 months) and 12 months (≥ 10 months) were also analysed. 
Additional inclusion criteria: (1) complete register data for MADRS-S, EASI, POEM, 
DLQI and pruritus intensity at baseline, (2) initiation of systemic AD treatment from 
January 10, 2017 through November 10, 2020. If the patient had several treatment episodes 
registered, only the first was included. 
 
30 
Study population: In total, 60 patients were included. Patients who had changed or stopped 
treatment (n = 13), had too short follow-up periods (n = 8) or no follow-up data (n = 3) at 
the 3-month follow-up or later were excluded from all follow-up analyses. Patients who 
changed or stopped treatment (n = 4) or had any missing data (n = 6) at 10 months or later 
were excluded from analyses at 12 months. At the 6-month follow-up, a total of 36 patients 
were included for further analysis. In total, 26 patients had complete records at baseline, 6 
months and 12 months. Information about prescriptions of antidepressants were obtained 
from the medical records of these patients. 
4.4 STATISTICAL METHODS 
All analyses were performed using SPSS, version 20 (IBM, Armonk, NY, USA). 
Bonferroni type adjustments were used because of multiple comparisons and the increased 
risk of type I errors in Study II. There were also used in a sub-analysis in Study V, as 
outlined below. In all other analyses, p-values < 0.05 were considered statistically 
significant. 
4.4.1.1 Descriptive and inferential statistics (characteristics) 
Baseline characteristics were expressed in proportions (%) of the total numbers of 
individuals observed, and continuous data as means with standard deviations (SDs) and/or 
medians with ranges. Independent samples were compared using Student’s t-test in Studies 
I–II and with the Mann-Whitney U-test in Studies IV–V, respectively. 
Weight change during systemic treatment were explored with non-parametric tests due to 
the small study population. In Study V, the primary outcome measure MADRS-S was 
considered to be an ordinal scale and normal distribution was not assumed for several of the 
other outcome measures. Therefore, non-parametric statistics were used. 
4.4.1.2 χ2 tests 
Categorical data and dichotomous variables were compared in terms of difference between 
proportions, using Pearson’s χ2 test. 
4.4.1.3 Conditional logistic regression 
The aim of conditional logistic regression is to describe an association between a binary 
outcome (e.g., disease yes/no) and possible independent variables (predictors or 
explanatory variables). The independent variables, often called covariates, may be 
continuous, dichotomous or categorical. Cases are matched with controls for at least one 
characteristic and the estimates are conditional on the matched set (by contrast, 
unconditional logistic regression is used in unmatched case-control studies). In Studies I–II, 
age and sex were used as matching variables. Conditional logistic regression was used to 
calculate odds ratios (ORs) as measures of the associations between AD and CVD and AD 
and autoimmune disease, respectively. 
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Due to the study design, AD was treated as the outcome and comorbidities as independent 
variables. All models used the matching variables in crude analyses. In multivariable 
analyses, potential confounders were included. A common cut-off for confounders is 
changing the OR > 10%; those were included in the adjusted odds ratio (aOR). Confounder 
selection was based on prior knowledge and in order to compare the study results with 
those of other studies within the field. This pragmatic approach to confounder selection 
may be used when complete knowledge on confounders is unavailable (123). 
4.4.1.4 Confidence interval 
A confidence interval (CI) is a range which contains the true value with a certain degree of 
probability. In Studies I–II, conditional logistic regression was used to calculate sex and 
age-adjusted crude and adjusted ORs with 95% CIs. 
4.4.1.5 Wilcoxon’s signed-rank test 
Wilcoxon’s signed-rank test was used for dependent follow-up data between start and 6 
months in patients on systemic AD treatment (Studies IV–V). 
4.4.1.6 Friedman’s repeated measurements analysis of variance  
Friedman’s repeated measurements analysis of variance (ANOVA) was used to analyse 
long-term follow-up, and pairwise comparison with Bonferroni correction was used to 
compare MADRS-S score differences at start and at follow-up after 6 and 12 months 
(Study V). 
4.4.1.7  Spearman’s rank order correlation 
The correlation between outcome measures (MADRS-S, EASI, POEM, DLQI and pruritus 
scores) was determined using Spearman’s rank order correlation (Study V). 
4.5 ETHICAL CONSIDERATIONS 
All studies within this thesis were approved by the Swedish Ethical Review Authority 
(Studies I–II Dnr: 2016/2496-31, Studies III–IV Dnr: 2010/345-31/2, Study V Dnr: 2021-
00394). 
The four principles of medical ethics are autonomy, non-maleficence, beneficence and 
justice (124). This section focuses on the ethical considerations within the research project. 
The respect for autonomy is linked to informed consent, where the patient makes an 
informed decision on whether or not to participate. Informed consent was not obtained for 
the case-control studies. In the Nordic countries, informed consent is rarely needed in large 
scale register-based research, but all research must be approved by an Ethics Committee 
(125). The arguments for this include that gathering informed consent would be cost-
ineffective, time-consuming and often practically impossible. It may also be difficult to 
obtain informed consent in certain high-risk groups of the population, some individuals will 
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be dead at the time the study ends, etc. Studies have shown that informed consent may lead 
to severe selection bias in large-scale epidemiological research (126). For the clinical 
studies, informed consent was always obtained. The patients were verbally informed about 
the AD quality register, that data could be used in research and that they could withdraw 
from the register at any time. 
The principle of non-maleficence is usually a minimal problem in large-scale 
epidemiological research, but all register-based studies include a risk of breaching the study 
person’s integrity. To minimise this risk, all data were anonymised before analysis and data 
were stored safely in accordance with the applicable regulations. All results were presented 
at group level. In the case-series, there was a risk of identification of individuals. Therefore, 
precautions were taken not to give too detailed information in the article. 
In the clinical studies, personal information was obtained through a web browser, but all 
communication between the web browser and the server was encrypted to protect personal 
data. Data in SwedAD are processed in accordance with the Swedish Personal Data Act 
(Personuppgiftslagen) and, as of 2018, the European Union’s General Data Protection 
Regulation. 
The clinical studies did not involve invasive procedures that could cause harm, and all tests 
and repeated visits were included in routine clinical care. The patients did complete several 
self-assessments and this may have been tiring and time-consuming, but I judge that the 
benefits from this standardised assessment of the AD, with the possibility for treatment 
modification, exceeded the ‘assessment burden’. 
The principle of beneficence involves a duty to benefit the patient. The clinical studies of 
AD patients involved a thorough check-up of the eczema, screening for adverse events and 
cardiovascular risk factors. If any abnormality was discovered, the patient received 
treatment or was referred for examinations or treatment. The study design enabled 
previously underreported adverse events of dupilumab to be detected and treated at an early 
stage. 
The principle of justice is often regarded as a form of fairness – in this context also 
distribution of risks and benefits to the participants. The case-control studies included the 
entire population, regardless of socioeconomic status or residence. Therefore, the results 
may benefit a large number of patients with AD, without causing harm to the participants. 
SwedAD has the purpose to continually improve the treatment and follow-up of all patients 
with AD on systemic treatment. By enrolling in the quality register, the participants not 





5.1 COMORBIDITIES OF AD (I, II, V) 
5.1.1 Cardiovascular disease (I) 
Baseline characteristics of patients with non-severe AD and severe AD are shown in Table 
7. Females were in the majority and there were more non-severe than severe AD cases. At 
the end of the study, participants with non-severe disease were younger than those with 
severe disease. The sub-analysis of women included mothers registered in antenatal care 
between 1982 and 2016: severe cases (n = 2,635) and non-severe cases (n = 27,985). 
Table 7. Characteristics of the study population. Patients with atopic dermatitis divided into 
severe cases and non-severe cases. 
 








Variable n = 9,558 
n (%) 
n = 93,013 
n (%) 
n = 95,274 
n (%) 
n = 929,422 
n (%) 
Sex   
 
 
0.860    
 
0.644 
  Women (%) 6,149 (64.3) 59,923 (64.4) 
 
63,101 (66.2) 616,257  (66.3) 
 
Age at end of study 
(y), mean (SD) 
53.5 ±15.7 53.8 ±15.8 0.070 41.0  ±16.7 41.3 ±16.8 < 0.001 
Age at end of study 










Years of education 
    
< 0.001 
    
< 0.000 
  ≤ 9 years (%) 1,889 (19.8) 19,442 (20.9) 
 
13,730 (14.4) 158,116 (17.0) 
 
  9–12 years (%) 4,634 (48.5) 41,698 (44.8) 
 
41,484 (43.5) 414,079 (44.6) 
 
  > 12 years (%) 3,035 (31.8) 31,873 (34.3) 
 
40,060 (42.0) 357,227 (38.4) 
 
Diabetes mellitus (%) 757 (7.9) 5,844 (6.3) < 0.001 3,222 (3.4) 32,272 (3.5) 0.146 
Hyperlipidaemia (%) 571 (6.0) 4,616 (5.0) < 0.001 2,642 (2.8) 24,128 (2.6) 0.001 
Hypertension (%) 2,007 (21.0) 15,280 (16.4) < 0.001 8,377 (8.8) 77,382 (8.3) < 0.001 
SD: standard deviation.                   
5.1.1.1 Overall 
In the crude sex-and age-adjusted analyses, there were significant associations between AD 
and angina pectoris (OR 1.18, 95% CI 1.13–1.23), MI (OR 1.10, 95% CI 1.04–1.15), and 
ischaemic stroke (OR 1.07, 95% CI 1.02–1.13). These associations were attenuated in the 
adjusted model, but remained for angina pectoris and MI (Table 8). AD was not associated 
with death from MI or ischaemic stroke. 
The adjusted estimate differed ≥ 10% when including smoking and hypertension, but not 
for other covariates. In line with previous studies, education, diabetes mellitus, 
hyperlipidaemia, and hypertension were included in the final adjustment model. 
Additionally, smoking and BMI were added for a subgroup of women. No effect 




Table 8. Risk of coronary artery disease and stroke in patients with atopic dermatitis (AD) 
compared with individuals without AD.  
Cases  
n = 104,832 
(%)  
All (fully adjusted)a 
OR 95% CI 
Men (fully adjusted)a 
OR 95% CI 
Women (fully 
adjusted)a OR 95% 
CI 
Angina pectoris 
       
AD total 2,719 (2.59) 1.13 (1.08–1.19) 1.10 (1.03–1.18) 1.16 (1.09–1.24) 
  Non-severe AD 2,194 (2.09) 1.13 (1.08–1.19) 1.12 (1.04–1.20) 1.15 (1.08–1.24) 
  Severe AD 525 (0.50) 1.11 (1.00–1.24) 1.04 (0.89–1.21) 1.19 (1.04–1.37) 
    Systemic 
    treatmentb 
    total 
 205 (0.20) 1.02 (0.87–1.21) 0.99 (0.78–1.26) 1.08 (0.85–1.35) 
Myocardial 
infarction 
       
AD total 2,264 (2.16) 1.07 (1.02–1.12) 1.12 (1.05–1.20) 1.01 (0.94–1.08) 
  Non-severe AD 1,801 (1.72) 1.07 (1.02–1.13) 1.15 (1.07–1.23) 0.98 (0.91–1.07) 
  Severe AD 463 (0.44) 1.03 (0.92–1.15) 1.01 (0.87–1.18) 1.06 (0.91–1.24) 
    Systemic 
    treatmentb  
    total 
  167 (0.16) 0.99 (0.82–1.18) 0.98 (0.76–1.25) 1.03 (0.79–1.34) 
Stroke 
       
AD total 1,975 (1.88) 1.04 (0.99–1.09) 1.09 (1.01–1.17) 1.00 (0.93–1.07) 
  Non-severe AD 1,538 (1.47) 1.00 (0.94–1.06) 1.06 (0.98–1.16) 0.95 (0.88–1.02) 
  Severe AD 437 (0.42) 1.19 (1.07–1.33) 1.20 (1.01–1.43) 1.19 (1.03–1.37) 
    Systemic 
    treatmentb  
    total 
 158 (0.15) 1.18 (0.98–1.41) 1.09 (0.82–1.46) 1.23 (0.98–1.56) 
Death from 
MI/stroke 
       
AD total 637 (0.6) 1.01 (0.93–1.10) 1.05 (0.92–1.18) 0.98 (0.87–1.10) 
  Non-severe AD 463 (0.44) 0.99 (0.90–1.10) 1.04 (0.90–1.20) 0.95 (0.82–1.09) 
  Severe AD 174 (0.17) 1.04 (0.88–1.23) 1.05 (0.82–1.35) 1.03 (0.82–1.30) 
    Systemic 
    treatmentb  
    total 
 33 (0.03) 0.84 (0.58–1.21) 0.65 (0.37–1.17) 1.02 (0.63–1.65) 
a) Adjusted for cardiovascular comorbidities (diabetes mellitus, hyperlipidaemia, hypertension) and years of 
education. b) Subgroup of patients with severe AD receiving systemic treatment (methotrexate, azathioprine, 
ciclosporin or mycophenolate mofetil). Significant differences in fully adjusted models in bold. OR: odds ratio; 
CI: confidence interval; MI: myocardial infarction. 
5.1.1.2 Non–severe atopic dermatitis 
Non-severe AD was associated with a higher risk of angina pectoris (aOR 1.13, 95% CI 
1.08–1.19) compared with controls and the association remained in analyses stratified by 
sex (Table 8). Men with non-severe AD had an association with MI (aOR 1.15, 95% Cl 
1.07–1.23). 
5.1.1.3 Severe atopic dermatitis 
Severe AD was associated with stroke (aOR 1.19, 95% CI 1.07–1.33) in both men and 
women. Compared with controls, severe AD cases had a higher prevalence of diabetes 
mellitus, hyperlipidaemia and hypertension (Table 7). There was no association between 
the use of systemic treatment and CVD. 
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5.1.1.4 Impact of education, smoking and BMI 
In the sub-analysis among mothers, severe AD cases presented with a higher prevalence of 
smoking (28.2% vs. 19.9%, p < 0.001) and obesity (12.0% vs. 9.6%, p < 0.001) compared 
with controls. In contrast, mothers with non-severe AD smoked less and were less 
overweight compared with controls. Among mothers with severe AD, the positive 
association with angina pectoris (n = 39) (OR 2.20 CI 1.50–3.24) decreased in adjusted 
models including smoking, BMI, education and cardiovascular comorbidities (aOR 1.51, CI 
1.00–2.28); adjustment for BMI only marginally changed the estimates. Among mothers, 
there were no significant associations with other CAD or ischaemic stroke in adjusted 
models.  
5.1.2 Autoimmune disease (II) 
Study II was based on the same study population as Study I. Baseline characteristics 
revealed that patients with AD were younger than controls at first diagnosis of any 
autoimmune disease (42.9 vs. 45.8 years, p < 0.001). Overall, AD was significantly 
associated with having one or more autoimmune diseases. This association grew stronger 
among AD cases with multiple autoimmune diseases (Figure 3). 
 
Figure 3. The number of autoimmune diseases in patients with atopic dermatitis (AD) and 







In the adjusted analyses, including education, the odds of having any autoimmune disease 
were almost doubled among AD cases compared with controls (aOR 1.97, 95% CI 1.93–
2.01). Associations were found between AD and diseases in several organ systems, 
especially for autoimmune diseases involving: 
(1) the skin (aOR 3.10, 95% CI 3.02–3.18); 
(2) the gastrointestinal tract (aOR 1.75, 95% CI 1.69–1.82), or 
(3) the connective tissue (aOR 1.50, 95% CI 1.42–1.58). 
The strongest associations between AD and autoimmune skin diseases were for dermatitis 
herpetiformis (aOR 9.76, 95% CI 8.10–11.8), alopecia areata (aOR 5.11, 95% CI 4.75–5.49) 
and chronic urticaria (aOR 4.82, 95% CI 4.48–5.19). 
5.1.2.1 Gender-specific associations 
Overall, men had a significantly stronger association between AD and autoimmune diseases 
than women (p < 0.0013) (Table 9). However, this sex difference was only statistically 
significant between AD and RA and AD and coeliac disease. Only males with AD had 
higher odds of DM1 (aOR 1.17 (1.08–1.27). Only females with AD had higher odds of 
dermatomyositis, systemic scleroderma, systemic lupus erythematosus, Hashimoto’s 
disease, Graves’ disease, MS, and polymyalgia rheumatica. Overall, no significant 
associations were found between AD and haematological or hepatic diseases; those results 




Table 9. Autoimmune diseases in patients with atopic dermatitis (AD) compared with 
individuals without AD. 
a Adjusted for sex, age and education. b Systemic lupus erythematosus. c Previously known as Wegener’s 
granulomatosis. Bold indicates P < 0.05. B (green) indicates statistical significance (P < 0.000427) after 
Bonferroni correction. * (yellow) indicates statistical difference in odds ratios between men and women (P < 
0.00128) after Bonferroni correction. OR: odds ratio; CI: confidence interval. 
Autoimmune disease by 
organ/tissue type 
Women (adjusted)a 












Any of the listed 
autoimmune diseases 
1.89 (1.85–1.93) < B 2.18 (2.10–2.25) < B < 0.0013 
      
Skin  3.01 (2.91–3.11) < B 3.29 (3.14–3.44) < B 0.002 
Dermatitis herpetiformis 9.00 (7.08–11.45) < B 11.02 (8.20–14.82) < B 0.299 
Alopecia areata 4.90 (4.51–5.32) < B 5.85 (5.04–6.78) < B 0.040 
Chronic urticaria 4.53 (4.16–4.92) < B 5.98 (5.14–6.96) < B 0.002 
Pemphigoid/pemphigus 3.22 (2.84–3.65) < B 3.55 (3.02–4.18) < B 0.355 
Vitiligo 2.43 (2.15–2.75) < B 2.98 (2.54–3.51) < B 0.048 
Psoriasis 2.43 (2.33–2.53) < B 2.71 (2.56–2.87) < B 0.002 
Gastrointestinal tract 1.67 (1.60–1.76) < B 1.94 (1.81–2.08) < B < 0.0013 
Coeliac disease 1.80 (1.67–1.94) < B 2.62 (2.31–2.97) < B < 0.0013 
Crohn’s disease 1.76 (1.62–1.92) < B 1.97 (1.75–2.22) < B 0.141 
Ulcerative colitis 1.50 (1.39–1.62) < B 1.72 (1.56–1.90) < B 0.033 
Connective tissue 1.46 (1.37–1.55) < B 1.63 (1.46–1.83) < B 0.083 
Dermatomyositis 3.09 (2.03–4.70) < B 1.81 (0.70–4.71) 0.223 0.314 
Systemic scleroderma 1.87 (1.40–2.49) < B 1.86 (0.87–3.95) 0.108 0.986 
SLEb 1.62 (1.39–1.88) < B 1.97 (1.23–3.14) 0.005 0.439 
Bechterew’s disease 1.51 (1.27–1.79) < B 1.41 (1.17–1.70) < B 0.616 
Rheumatoid arthritis 1.35 (1.25–1.46) < B 1.83 (1.58–2.13) < B < 0.0013 
Polymyositis 1.73 (1.06–2.82) 0.028 0.44 (0.11–1.82) 0.258 0.074 
Vascular 1.32 (1.16–1.50) < B 1.48 (1.21–1.81) < B 0.348 
Temporal arteritis 1.42 (0.73–2.77) 0.303 3.50 (1.26–9.77) 0.017 0.149 
Granulomatosis with 
polyangiitisc 
1.52 (1.04–2.22) 0.030 1.75 (1.04–2.93) 0.035 0.672 
Polymyalgia rheumatica 1.32 (1.15–1.51) < B 1.39 (1.11–1.73) 0.004 0.696 
Neuromuscular 1.26 (1.13–1.41) < B 1.27 (1.03–1.57) 0.027 0.952 
Multiple sclerosis 1.26 (1.12–1.42) < B 1.34 (1.05–1.72) 0.019 0.652 
Guillain-Barré syndrome 1.41 (0.86–2.32) 0.169 1.11 (0.64–1.93) 0.705 0.526 
Myasthenia gravis 1.11 (0.75–1.64) 0.598 1.04 (0.54–2.00) 0.909 0.862 
Endocrine 1.12 (1.07–1.17) < B 1.21 (1.12–1.30) < B 0.088 
Addison’s disease 1.16 (0.78–1.71) 0.462 2.04 (1.29–3.23) 0.002 0.066 
Hashimoto’s disease 1.38 (1.22–1.55) < B 1.16 (0.73–1.84) 0.542 0.476 
Graves’ disease 1.15 (1.07–1.23) < B 1.39 (1.14–1.68) 0.001 0.079 
Diabetes mellitus type 1 1.02 (0.95–1.10) 0.567 1.17 (1.08–1.27) < B 0.012 
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5.1.2.2 Impact of heredity and smoking 
In subgroup analyses among 92,290 AD cases, after adjustment for any parental 
autoimmune disease, the association between AD and autoimmune disease remained stable 
(aOR 1.90, 95% CI 1.86–1.94 vs. OR 1.89, 95% CI 1.86–1.93). Similar results were 
observed in models comprising specific parent-offspring associations for 15 of the most 
common autoimmune diseases (data not shown). In the sub-analysis among women (n = 
32,797), all associations between AD and autoimmune dermatological, gastrointestinal and 
rheumatological diseases and MS remained significant after adjustment for smoking (OR 
changed < 0.10) (data not shown). 
No statistically significant interactions were found between autoimmune diseases and any 
of the included covariates. 
5.1.3 Depression (V) 
Among the 60 patients with AD eligible for analyses, females represented 38.3% (Table 
10). In total, 13 (21.7%) met the criteria for moderate depression, 2 (3.3%) met the criteria 
for severe depression and 3 (5%) presented with marked suicidal ideation. There was no 
significant difference in median EASI score between the 15 (25%) patients with moderate-
to-severe depression (median EASI score 19.0, range 1–46) and the 45 (75%) patients with 
lower MADRS-S scores (median EASI score 19.0, range 1–50). 
The median EASI scores were significantly higher among males than females. More 
females than males had a history of hand eczema within the preceding 12 months. There 
were no other significant differences of baseline characteristics with respect to sex. Work 
limitation due to eczema was significantly associated with higher MADRS-S score (p < 




Table 10. Baseline characteristics of patients with atopic dermatitis on systemic treatment. 
  All cases Women Men P-value 
Variable n = 60 n = 23 n = 37 
Sex, n (%)  23 (38.3)   37 (61.7)   
Age (years), median (range) 47.5 (19–77) 48.0 (19–68)   47.0 (19–77)   0.791 
MADRS-S, median (range) 13.5 (0–50) 14.0 (1–26)   13.0 (0–50)   0.426 
  No depression, n (%)      
0.251 
   MADRS-S 0–12 p  27 (45.0) 9 (39.1)  18 (48.6)  
  Light depression, n (%)      
   MADRS-S 13–19 p  18 (30.0) 10 (43.5)  8 (21.6)  
  Moderate depression, n (%)      
   MADRS-S 20–34 p  13 (21.7) 4 (17.4)  9 (24.3)  
  Severe depression, n (%)      
   MADRS-S ≥ 35 p  2 (3.3) 0 (0)  2 (5.4)  
EASI, median (range) 19.0 (1–50) 13.0 (3–38)   22.0 (1–50)   0.047* 
Educationa         
  ≤ 9 years (%) 6 (10.3) 2 (9.5)  4 (10.8)  
0.679   9–12 years (%) 26 (44.8) 11 (52.4)  15 (40.5)  
  > 12 years (%) 26 (44.8) 8 (38.1)  18 (48.6)  
Facial eczemab 41 (68.3) 15 (65.2)   26 (70.3)   0.682 
Hand eczemab 37 (61.7.) 18 (78.3)  19 (51.4)  0.037* 
Work limitation due to eczemac 17 (37.8) 5 (27.8)   12 (44.4)   0.259 
Alcohol consumptiond       
   Never 13 (22.8) 6 (30.0)  7 (18.9)  
0.756 
   1 time/month or less 6 (10.5) 2 (10.0)  4 (10.8)  
   2–4 times/months 25 (43.9) 8 (40.0)  17 (45.9)  
   2–3/times/week 7 (12.3) 3 (15.0)  4 (10.8)  
   4 times a week or more 6 (10.5) 1 (5.0)  5 (13.5)  
Antidepressantse (n) 9 (15.0) 6 (26.1)   3 (8.1)   0.058 
MADRS-S: Montgomery-Åsberg Depression Rating Scale–Self-report; EASI: Eczema Area Severity Index; 
Independent samples were tested with the Mann-Whitney U-test. Pearsons’s χ2 test was used to compare the 
proportions between sexes for the following variables: education, ongoing stress, eczema location, work 
limitation and alcohol consumption. Significant differences marked with *. 
Footnotes: a Missing n = 2. b During the preceding 12 months c Missing n = 15. Students, pensioners and 
unemployed excluded. d Missing n = 3. e Patients with antidepressants at baseline or who were prescribed 
antidepressants during the follow-up period. 
5.2 ADVERSE EVENTS OF SYSTEMIC AD TREATMENT (III, IV) 
5.2.1 Ocular adverse events (III) 
In the case-series, ocular adverse events were very common: 9/10 developed eye problems 
(Table 11). Seven patients were diagnosed with conjunctivitis (Figure 4). Serious ocular 
adverse events included uveitis due to reactivation of herpes simplex virus (HSV). One 
patient who presented with blisters on the eyelid was 2 days later hospitalised with a 
diagnosis of varicella-zoster virus (VZV) meningitis. The patients with HSV and VZV 
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infections recovered and continued with dupilumab, but antiviral prophylaxis was added. 
One patient stopped dupilumab due to conjunctivitis, whereas all others improved with eye 
treatment (as presented in Table 11) and continued with dupilumab. 
Overall, outcome measures improved during treatment. The mean EASI score at baseline 
was 20.7 (range 4.8–46.5). At 3 months, 2 of 10 patients showed complete clearance, 4 
patients achieved EASI-90, and 2 patients achieved EASI-75. One patient who decided to 
stop dupilumab after 3 months due to severe conjunctivitis had almost cleared skin at that 
timepoint. The positive effect of dupilumab on the outcome measures overall increased 
and/or remained stable at follow-up after 5–7 months. However, one patient with FLG 
mutation did not achieve EASI-50. 
 
Figure 4. Severe conjunctival reaction with redness, dilated conjunctival vessels and limbal 




Table 11. Characteristics of 10 patients with severe atopic dermatitis treated with dupilumab. 







history of eye 
diseasea  
Adverse events Ophthalmological 
treatment 
1 Yes Yes WT No Conjunctivitis, 
photophobia, 
dry eyes 
Vaseline eye ointment, 
artificial tears 





Tacrolimus eye ointment 
0.1%  
3 Yes Yes HeZ No Kerato-
conjunctivitis 
Tacrolimus eye ointment 
0.1%, artificial tears 
4 Yes Yes HoZ Herpes simplex 
virus uveitis 
with secondary 
glaucoma 2 yrs 
earlier 
Herpes simplex 
virus uveitis with 
secondary 
glaucoma 




drops 1 mg/ml, 
glaucoma treatment 





Prednisolone pivalate 5 
mg/g 1x1 eye ointment, 
artificial tears 










Tacrolimus eye ointment 
0.1%, Vaseline eye 
ointment 










IV acyclovir with 
continuing antiviral 
prophylaxis 
8 Yes Yes WT No Conjunctivitis Vaseline eye ointment, 
artificial tears 




3 mg/ml/1 mg/ml eye 
drops, 
artificial tears, paraffin 
Vaseline ointment 




after 3 months 
due to 
conjunctivitis.) 




3 mg/ml/1 mg/ml eye 
drops, artificial tears 
aRequiring ophthalmologic examination. WT: wild-type; HeZ: heterozygous; HoZ: homozygous.  
 
5.2.2 Weight gain (IV) 
Baseline BMI was comparable between the treatment groups of dupilumab (n = 12) and 
MTX (n = 8). Dupilumab-treated patients presented with BMI 27.3 (95% CI 24.0–28.4), 
and MTX-treated patients with BMI 24.7 (95% CI 19.9–36.1). There were no significant 
differences in age, sex, POEM scores, pruritus scores or MADRS-S scores between the two 
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treatment groups at baseline, but the patients treated with dupilumab had a significantly 
higher EASI scores (p = 0.045) and the patients treated with methotrexate had significantly 
higher DLQI scores (p = 0.025). 
• After one year, body weight increased by a mean of 6.1 kg, range 0.1–18.0 (p = 
0.002) in AD patients treated with dupilumab, while those treated with MTX did not 
show any significant weight change. 
5.2.2.1 Weight change in relation to treatment response 
A subgroup analysis was performed among patients successfully treated with dupilumab (n 
= 11) or methotrexate (n = 6), in order to explore if the results remained or if they could be 
explained by good treatment response. Successful treatment response was defined as 
achievement of EASI-75 or improvement in EASI score ≥ 6.6 at the 6-month follow-up. 
(1) The mean weight change among successfully treated patients with dupilumab was 
comparable with that of all patients treated with dupilumab. Among patients 
successfully treated with MTX, weight was reduced (-4.3 kg, range -17 to 2.0), but 
this change was not significant. 
(2) Among successfully treated patients, there was no correlation between weight gain 
and appetite scores (all treatments). 
(3) Among AD patients successfully treated with dupilumab, 5 had improved sleep at 
follow-up, and 5 had unchanged sleep (missing data for one person). All gained 
weight significantly, regardless of sleep improvement. 
(4) Among patients successfully treated with MTX, all had improved night sleep during 
treatment and they did not gain weight (mean weight change -4.3 kg). The absolute 
number of nights with improved sleep tended to be lower among patients treated 
with MTX than among patients treated with dupilumab. 
5.3 EFFECTS OF SYSTEMIC AD TREATMENT ON DEPRESSIVE SYMPTOMS 
AND OTHER OUTCOMES (V) 
5.3.1 Outcome measures at 6 months 
Among 36 patients with AD, treated with ciclosporin (n = 1), MTX (n = 8) or dupilumab (n 
= 27), who completed follow-up at 6 months, all outcome measures significantly improved 
(p < 0.001). The results remained stable both when the treatments were analysed separately 
and when analysed as a group, but MADRS-S scores were significantly lower in the 
dupilumab group at 6-month follow-up. Altogether, the median MADRS-S score change 
was -5.0 (range -36 to +5, p < 0.001). In a sensitivity analysis, the significant MADRS-S 
score reduction between start and 6 months remained when all patients who were on 
antidepressants (n = 8) during the study period were excluded (data not shown). Four 
patients who had used antidepressants for at least 3 months before the start of the study 
period and throughout follow-up tended to improve their MADRS-S score, from median 17 
(range 8–25) to median 11 (range 4–14), p = 0.066. 
 
 43 
At the 6-month follow-up, patients who achieved EASI-90 did not have a significantly 
different median MADRS-S score (median MADRS-S score 4.5, range 0–14) compared 
with patients who did not achieve EASI-90 (median MADRS-S score 7.0, range 0–22). A 
similar finding also applied to responders and non-responders for EASI-75 and EASI-50, 
respectively. Spearman’s correlation coefficients for all registered MADRS-S scores (at 
start and 6 months) revealed a significant correlation with EASI score (r = 0.386, p = 
0.001), POEM score (r = 0.557, p < 0.001), DLQI score (r = 0.623, p < 0.001) and pruritus 
score (r = 0.436, p < 0.001). 
Of three patients with marked suicidal ideation, two were included at the 6-month follow-
up. Both had improved their item 9 scores in MADRS-S to ≤ 2 (‘enjoys life or takes it as it 
comes’/‘only fleeting suicidal thoughts’). One patient changed systemic treatment to 
dupilumab at 3 months of the study and was therefore excluded from the follow-up 
analysis. The item 9 score of this subject improved to 0 at 6 months. None of the three 
patients with marked suicidal ideation received antidepressants during the study period. 
5.3.2 MADRS-S items (0–6 months) 
Sleep impairment was highest at start, with a median score of 3.0 (range 0–6). All different 
aspects (items) of MADRS-S were significantly improved during the follow-up period, 
including suicidal ideation (Figure 5). Furthermore, there was a significant correlation 
between sleep disturbance outcomes in POEM and in MADRS-S (r = 0.608, p < 0.001). 
 
Figure 5. Boxplot showing medians, interquartile ranges and ranges of items in 
Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S) at baseline and 
follow-up at 6 months among 36 adults with atopic dermatitis on systemic treatment. Means 
marked with x.  
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5.3.3 Outcome measures at 12 months 
Among the 26 patients who completed the 12-month follow-up (Figure 6), the significant 
improvement of MADRS-S score and other outcome measures remained. 
 
Figure 6. The effect of systemic AD treatment (dupilumab n = 23, MTX n = 3) on outcome 
measures in 26 patients who completed follow-up at 6 and 12 months. MADRS-S: 
Montgomery-Åsberg Depression Rating Scale–Self-report; EASI: Eczema Area Severity 
Index; POEM: Patient-Oriented Eczema Measure; DLQI: Dermatology Life Quality Index; 
Pruritus: 0–10 cm visual analogue scale (VAS)/0–10 numeric rating scale (NRS-11). P-values 
calculated with Friedman’s repeated measurements analysis of variance. Footnotes: a Values 
collected at 6 ± 3 months. b The 12-month follow-up range for EASI was 10.0–23.0 months, 







6.1 MAIN FINDINGS AND IMPLICATIONS 
6.1.1 Associations between AD and CVD (I) 
In Study I, an association was seen between AD and angina pectoris, MI and ischaemic 
stroke compared with the general population. The association between AD and ischaemic 
stroke was significant only among cases with severe AD. The results remained in 
multivariable adjustments for education and cardiovascular comorbidity. These findings are 
supported by previous studies (57, 58, 127), but no association between AD and 
cardiovascular death was found. 
Subgroups were identified in which the associations varied and possible explanations were 
found for some, but not all, subgroup patterns. Overall, there was an association between 
AD and angina pectoris, but this was not found among men with severe AD. Men with non-
severe AD had an association with MI, but this was not found in the severe groups or 
among women. Severe AD had an association with stroke among both men and women. 
Results stratified by sex have rarely been reported in previous studies of AD. On the other 
hand, the risk of MI is approximately 3 times higher among men than women in the general 
population. The incidence becomes more similar with increasing age, especially among 
women with risk factors for CVD (128). This may explain why an association between AD 
and MI was found among men, but not among women. 
As previously discussed, several studies have explored the relation between AD and CVD, 
but with conflicting results (55-57, 129). Mixed findings may be due to several factors, 
such as differences in study design, definitions and diagnosis of AD (e.g., questionnaire-
based diagnosis, diagnosis by a general practitioner or by a dermatologist). Only a few 
studies have adjusted for important risk factors for CVD, such as smoking. Unfortunately, 
adjustment for smoking was not possible among all subjects in Study I. However, in a 
subgroup of women, adjustments for smoking could be made and changed the estimates 
between severe AD and angina pectoris, but it did not change the overall estimates in the 
non-severe group. In study 1, our interpretation was that smoking may be an important 
confounder in severe cases. Nevertheless, one must be careful of generalising this result, as 
the subpopulation of women registered in antenatal care was younger than the main study 
population. 
The findings are consistent with previous studies indicating that severe AD is associated 
with several risk factors for CVD, although data are limited (60). Among severe AD cases, 
there was significantly higher prevalence of cardiovascular comorbidities, including 
diabetes mellitus, hyperlipidaemia and hypertension, compared with controls. Subgroup 
analyses among women indicated that severe AD cases had significantly lower education 
levels, and higher prevalence rates of smoking and obesity compared with controls. 
Notably, mothers with non-severe AD smoked less and had less overweight than control 
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subjects. Additionally, in Study V, it was found that 25% of AD patients with moderate-to-
severe AD presented with a moderate-to-severe depression – another possible risk factor for 
CVD. 
Thus far, most associations between AD and CVD have been described as epidemiological. 
Whether or not there is a causal relationship remains unknown. Due to the design of Study 
I, it was not possible to explore if adults with AD were at greater risk for cardiovascular 
events. Nevertheless, the small effect size and lack of biological gradient did not support a 
causal relationship. Overall, no consistent gradient based on disease severity was seen. 
According to the Bradford Hill criteria, a greater exposure should generally lead to a greater 
incidence of the effect, and such a finding would support that the association is based on a 
causal relationship (130). The relative risk for CVD has been reported to be high in some 
high-quality studies (57), but the absolute risk may be considered low (131). Data from the 
large cohort study by Silverwood et al. showed that AD patients had 12 more heart attacks 
and 25 more strokes per 100,000 person-years compared with healthy controls (57). 
In my experience, it would seem that most epidemiological studies in this field publish low 
odds ratios. Maybe any potential great discovery would already have been revealed by 
smaller studies in a clinical setting long ago, without advanced computer programs. This 
would be analogous to gold prospecting, where a simple gold pan was enough for gold 
detection in the past. Today, we need highly sensitive technological methods to find any 
gold at all. However, ORs in the lower range can also be important. Especially if more 
advanced interaction models enable the identification of subsets of patients at very high risk 
of CVD among millions of subjects with AD, but the average AD patient would present 
with an OR of about 1.0. 
In summary, the findings in Study I support an association between AD and CVD, although 
the magnitude of this association might be considered low. Regardless of any definite 
causal relationship between AD and CVD, increased awareness and screening of 
cardiovascular risk factors may be recommended, especially among severe AD cases. 
6.1.2 Associations between AD and autoimmune disease (II) 
In Study II, an association was found between AD and several autoimmune diseases, 
especially those involving the skin, the gastrointestinal tract or the connective tissue. 
Overall, these findings are in line with previous studies (73, 74, 132-135). Furthermore, a 
dose-response relationship was observed between the number of autoimmune diseases and 
the association with AD. The strongest associations between AD and specific skin diseases 
were found for dermatitis herpetiformis, alopecia areata and chronic urticaria. 
A weak association between AD and DM1 was observed among men, but not women. 
Previous studies have conflicting results on the association between AD and DM1 (74), 
supporting the view that this finding should be interpreted with caution. Furthermore, an 
association with MS was found – where previous data have also been conflicting, although 
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based on few studies – as were associations with Graves’ and Hashimoto diseases, which 
were not found in a previous study (73). In addition to the previously discussed reasons for 
between-study variations, statistical cut-off points vary widely between different studies. 
For most autoimmune diseases, there is a clear sex difference in prevalence: 80% of 
individuals with autoimmune diseases are women (136). In order to show this important 
aspect of comorbidity, men and women have been presented separately. Several differences 
between males and females were found, e.g., men with AD had a stronger association 
between RA and coeliac disease than women. AD was associated with several 
rheumatologic and endocrine diseases, and MS, in women only. Various mechanisms for 
sex differences in autoimmune diseases have been put forward, such as genetic 
predisposition and heightened immune reactivation in women (137). Speculatively, a 
heightened immune reactivity may also explain why females with AD have been observed 
to have more persistent AD than males (138). 
A broad definition of autoimmune disease was used in order to replicate and compare the 
results with those of earlier studies that used a similar definition. The primary focus of 
Study II was to explore any associations between AD and autoimmune disease, not to study 
the mechanisms, genetics, or temporal relationship behind these associations. Nevertheless, 
some findings might give deeper insight into the relationship between AD and autoimmune 
diseases. Smoking, education and hereditary status may influence the association with 
several diseases, but including these variables in multivariable analyses did not change the 
results. Interestingly, it could be noted that patients with AD were generally diagnosed with 
autoimmune disease earlier in life than controls. This, and the observed dose-response 
relationship between AD and autoimmune diseases, may support the idea of an autoimmune 
component of AD and/or shared immune pathways and environmental factors yet to be 
discovered. 
Greater awareness and screening of comorbidities among adult AD patients might relieve 
the disease burden of AD. Further, increased knowledge of comorbidities could enable 
physicians to provide more personalised treatment. Some new and emerging JAK inhibitors 
for AD might be used to treat both AD and autoimmune diseases. The JAK-STAT pathway 
is involved in the pathogenesis of multiple diseases, including RA, psoriatic arthritis, 
inflammatory bowel disease, and AD (139).  
6.1.3  Association between AD and depression  (V) 
In Study V, more than half of the patients with moderate-to-severe AD eligible for systemic 
treatment of AD had depressive symptoms, 25% of whom presented with a moderate-to-
severe depression and 5% of whom had pronounced suicidal ideation. 
The high prevalence of depression was consistent with previous data (79). However, the 
overall prevalence of depressive symptoms was higher than in a recent meta-analysis in all 
ages (55% vs. 22%) (80). The explanation may be that the patients in Study V had a more 
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severe AD than in several other studies. Depression has been observed to be driven by AD 
severity (140, 141). Moreover, Study V included only adults. The prevalence of suicidal 
ideation was lower than in a recent meta-analysis (5% vs. 12.2%) (80). Differences may be 
due to diversity in study design, outcome measures and definitions of suicidal ideation. The 
findings of Study V were in line with a German cross-sectional study where 7 of 181 
(3.9%) exhibited symptoms indicating a suicidal crisis (142). 
The results supported the hypothesis that disturbed sleep due to itching is associated with 
depressive symptoms among AD patients. Further, an association was found with work 
limitation and depressive symptoms, which could have a negative impact on HRQoL and 
financial burden. The findings did not support that facial eczema, possibly leading to 
psychosocial stigmatisation, was associated with depression. 
The magnitude of depression was higher than expected, as was the number of patients with 
suicidal ideation. The prevalence of depression among moderate-to-severe AD patients 
maybe be underestimated and more attention should be paid to this. A previous case-control 
study found that two thirds of patients with eczema who died from suicide had visited a 
doctor in the month before death (143). The last visit had most often been with a family 
doctor, but 1 in 25 among patients with persistent eczema had visited a dermatologist at 
their last healthcare visit. The use of MADRS-S or other self-assessment tools can be 
helpful to detect depressive symptoms and suicidal ideation that are not easily captured 
otherwise. 
6.1.4 Eye complications during dupilumab treatment (III) 
In Study III, ten patients treated with dupilumab were observed and the outcome measures 
improved in the majority. Ocular adverse events were much higher than expected, with 
90% developing eye problems (i.e., blepharitis, conjunctivitis, uveitis and keratitis). We 
found that 70% of the patients developed conjunctivitis, whereas clinical trials had reported 
a much lower incidence (8.6% to 22.1%) (144-146). 
This study was among the first to report dupilumab-associated conjunctivitis as a common 
adverse event. The same observation has since been replicated in several real-world studies 
(99). In line with these observations, severe and long-lasting AD, good response to 
treatment and/or previous eye disease (pre-existing conjunctivitis or atopic 
keratoconjunctivitis) have been associated with an increased risk of conjunctivitis (147, 
148). The contradictions of findings between real-world studies and clinical trials have 
several potential explanations. Clinical trials use strict eligibility, i.e., patients with certain 
comorbidities and patients with certain profiles are excluded. In most trials, AD patients 
were excluded if they had used systemic treatment during the run-in period (which was 4 
weeks in early dupilumab trials) or topical glucocorticoids within 1 week of baseline (145). 
Thus, some severe AD patients may have had difficulties to qualify for or enter the trial. 
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The pathomechanism behind dupilumab-associated conjunctivitis is not clarified. It is also 
unknown why ocular adverse events are more common among patients with AD compared 
with patients where dupilumab is used for asthma, chronic rhinosinusitis or eosinophilic 
esophagitis (149). Bakker et al. performed conjunctival biopsies among 6 AD patients with 
dupilumab-associated conjunctivitis (150). They found a prominent inflammatory T cell 
infiltrate (mainly CD3+/CD4+ cells) and more eosinophils compared with in healthy 
controls. The most noticeable feature among AD patients was a scarcity of mucus-
containing goblet cells. It has been demonstrated that IL-13 stimulates these cells to 
proliferation and mucus secretion, which is important for ocular surface functions (150). 
Therefore, effective blocking of IL-13 may cause dry eyes and conjunctival inflammation 
leading to keratoconjunctivitis, especially among predisposed patients (147). It has also 
been suggested that dupilumab increase Demodex numbers by compromising the Th2 
signalling (151). This could cause an IL-17-mediated ocular inflammation and 
conjunctivitis as described in rosacea, but the role of Demodex in dupilumab-associated 
disease is debated (152). Other explanations include dupilumab-associated eosinophilia. 
These cells play a role in the development of allergic eye conditions (153). 
Based on real-life data, where the findings of Study III contribute to the body of 
knowledge, conjunctivitis has been confirmed to be the most common of all dupilumab-
associated adverse events (99). In light of this, new treatment algorithms have emerged 
(149, 154). According to these guidelines, it is appropriate to recommend preservative-free 
lubricating eye drops as a prophylactic treatment for patients with AD initiating dupilumab. 
Based on data from recent literature, most dupilumab-associated conjunctivitis resolves 
with conservative treatment and discontinuation of dupilumab is rarely needed (146, 149). 
Referral to an ophthalmologist is recommended if ocular symptoms are not relieved with 
conservative treatment, such as artificial tears, and/or if there are any signs of severe ocular 
manifestation or infection. With increased awareness of ocular adverse events, including 
early diagnosis and treatment, patients with AD have a higher likelihood to continue with 
dupilumab. 
6.1.5 Weight gain during dupilumab treatment (IV) 
In Study IV, we reported a significant weight gain among patients treated with dupilumab. 
The mean weight gain was 6.1 kg after one year of treatment. To the best of my knowledge, 
this is the first study reporting weight gain as a possible dupilumab-associated adverse 
event. We did not find any correlations between weight gain and treatment response, 
disturbed sleep due to itching or changed appetite. Patients with MTX treatment did not 
gain weight. We have not found any previous reports of weight gain through blockade of 
the shared IL-4α subunit, the target of dupilumab, but changes in body weight have been 
reported for other biologics. Patients with psoriasis have been observed to gain weight 
during treatment with TNF-α (155), and RA patients to gain weight during treatment with 




Scratching due to itching and restlessness during disturbed night sleep may be energy-
consuming. As a result of this, improved AD symptoms during treatment could 
hypothetically lead to increased fat mass. In Study IV, weight change was observed among 
patients successfully treated with dupilumab, but not among patients successfully treated 
with MTX. Our interpretation was that weight change might be related to the mechanisms 
of the treatment, without a direct link to AD treatment outcomes. We assumed that patients 
with MTX would have stopped treatment during the follow-up period if gastrointestinal 
side effects, such as nausea, were a major concern. 
In conclusion, a significant weight gain among patients treated with dupilumab was 
observed, but possible mechanisms behind this remain unclear. Despite the limitations of a 
small study population, these results may serve as an indication that more attention should 
be paid to patients with weight gain. This may be especially important among severe AD 
patients with other cardiovascular risk factors. Further research and larger studies are 
needed to confirm and explore this novel finding. 
6.1.6 The effect of systemic AD treatment on depressive symptoms (V) 
In Study V, systemic treatment of AD significantly reduced all aspects of depressive 
symptoms, including suicidal ideation and disturbed sleep, and all other outcome measures 
at 6 months. This positive effect remained stable at 12 months. Studies exploring the effect 
of systemic treatment on depression are limited outside clinical trials, but the findings are in 
line with phase III trials of dupilumab where significant reduction of depressive symptoms 
was demonstrated. Both MTX and dupilumab improved these, but Study V suggested that 
dupilumab was more effective than MTX. In Study V, three patients with marked suicide 
symptoms radically improved their scores of suicidal ideation during systemic AD 
treatment without concomitant antidepressants. 
There are several possible explanations why systemic treatment could reduce depressive 
symptoms. Itch and sleep disturbances appear to worsen with AD severity, and sleep 
disturbance is an independent risk factor for depression (83). Effective systemic treatment 
of AD, targeting both the skin inflammation, itch and sleeping disturbances, and perhaps 
neuroinflammatory pathways yet to be discovered, might reduce depressive symptoms. 
Study V supported that effective AD treatment can reduce depressive symptoms. Moreover, 
depressive symptoms in patients with moderate-to-severe AD might improve from systemic 
treatment in addition to traditional antidepressants. 
6.2 METHODOLOGICAL CONSIDERATIONS 
The strengths of the case-control studies (I–II) were the use of nation-wide large 
population-based cohorts with high-quality register data. Further, a large study population 
gave substantial power and enabled stratification into subgroups. The strengths of the 
prospective clinical cohort studies, including the case-series, were the use of validated 
outcome measures as defined by HOME, and AD diagnoses made by dermatologists. 
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Studies III–V observed outcomes for a novel treatment and contributed to new knowledge. 
The latter may generate hypotheses that should lead to larger studies with higher level of 
evidence. However, the thesis also has several limitations. The major methodological 
considerations are discussed below. 
6.2.1 Study design 
A case-control study design was used to study the association between AD and CVD or 
autoimmune diseases. This design has several advantages, such as being efficient in terms 
of money, time and effort, but it is more vulnerable to bias than comparable designs (157). 
By defining AD as the outcome, several exposures could be studied within the same 
dataset, which was very efficient. A major limitation was that it was not possible to 
estimate incidence rates or assess if AD was a risk factor for CVD and/or autoimmune 
disease. If the prevalence of an outcome is low (usually under 5%) among both those 
unexposed and those exposed, the odds ratio (OR) can be interpreted as an estimate of the 
relative risk (158). The estimated 12-month prevalence of AD (all continents included) is 
up to 17.1% among adults (159). Therefore, the research team considered the ORs likely to 
be more interesting as measures of association between AD and other diseases than as 
measures of how much higher the risk for AD was among people with or without 
CVD/autoimmune disease. If a cohort design had been used, enabling calculation of 
incidence rate, the study population would have been defined by their exposure status (AD 
vs. no AD) and followed over time to estimate the incidence of disease. The advantage 
would have been seen for diseases occurring later in life, such as CVD, with good coverage 
in the NPR and death register, and with information about date of illness onset or death. 
This would not apply to several of the autoimmune diseases where date of illness onset is 
more uncertain. Further, the date of start of symptoms with AD may be uncertain and data 
from primary care are not available in the NPR. 
The major limitations of the clinical studies (III–V) were the small study populations, 
which may have led to unreliable and hard-to-replicate results, and a lack of sufficient 
control subjects. Unfortunately, in Study V, several of the included patients had too short 
follow-up periods for a longitudinal analysis. The participants with too short follow-ups 
were comparable with the participants included in the longitudinal analysis at baseline, and 
hopefully this loss-to-follow-up did not affect the findings. 
6.2.2 Validity 
The validity of a research project encompasses two components. External validity refers to 
how generalisable the results are for the population that the sample represents. Internal 
validity refers to if the findings within the population can be trusted and are not due to 
methodological errors. In other words, there is no external validity without internal validity 
(160). A study is valid if we can exclude systematic errors (also called bias) and random 
errors, thus leading to a correct assessment of the exposure and outcome. There are 
numerous types and sources of bias, several of which apply to this thesis. In observational 
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studies, the major threats to internal validity are selection bias, information bias and 
confounding (158). 
6.2.2.1 Selection bias 
Selection bias occurs when the association between an exposure and disease differs 
between participants and non-participants in a study (161). The result is a study population 
that is not a representative sample of the target population. Ascertainment bias (also known 
as detection bias) occurs when certain participants are more likely to be included. In the 
case-control studies (I–II), ascertainment bias cannot be excluded if AD patients who had 
seen a doctor or been hospitalised for other problems (CVD or autoimmune disease) were 
more likely to be diagnosed with AD. Moreover, some clinics have reimbursement systems 
based on diagnosis-related groups, which may have led to listing of multiple diagnoses at a 
visit. Bias caused by diagnosis-related groups should be minor in this study, because the 
majority of the autoimmune diagnoses and cardiovascular diseases have strict definitions 
and were made by specialists within their respective medical disciplines. In Study IV, 
selection bias cannot be excluded if patients gaining weight were more likely to measure 
their weight, and missing weight data led to an exclusion of cases without this side effect. 
Nevertheless, I believe this scenario was uncommon, as weight is a routine outcome 
measure. 
6.2.2.2 Information bias 
Information bias results from an incorrect measurement of exposure and/or outcome (158). 
It is also known as observation, classification or measurement bias. The effect of 
information bias will depend on the type of misclassification: non-differential or differential 
(160). Non-differential misclassification occurs when the bias or measurement error occurs 
with equal likelihood among cases and controls. In Study I, we cannot exclude non-
differential measurement errors of weight and smoking reported among mothers registered 
at antenatal care. Such erroneous data would dilute the effect of these variables toward the 
null, since measurement errors most likely occurred among all mothers, regardless of a 
diagnosis of AD or not. Differential misclassification refers to differences in 
misclassification between cases and controls and will result in an estimate shifted either 
upward or downward from null, depending on who is misclassified. The main differential 
misclassification bias probably occurred in the case-control studies with misclassification 
of the diagnosis of AD, severity of AD and/or comorbidities. Reporting bias cannot be 
excluded in the clinical studies (III–IV). 
Misclassification of AD may have occurred as the research team had no data from primary 
care and might therefore have missed some cases who had never received an AD diagnosis. 
However, since the AD diagnosis can be a challenge and misdiagnosis may occur, a major 
strength was that 80% of the AD patients had received their diagnosis in a dermatology 
department, thus reducing the overall risk of misclassification. It should also be recognised 
that some misclassification of AD can occur if a doctor is more likely to give an AD 
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diagnosis due to the reimbursement for this diagnosis. In some clinics, it is more favourable 
to make an ICD diagnosis of AD than to use the ICD code for unspecific dermatitis.  
Misclassification of disease severity is linked to the study definition of severe AD vs. non-
severe AD. In Study 2, we chose this definition of non-severe AD and severe AD to make 
that study comparable to other studies with similar definitions of disease severity. Severe 
AD included patients prescribed conventional systemic treatment for AD or who had been 
treated in a dermatological ward with AD as their main diagnosis. Patients without systemic 
AD treatment, even if they had been treated by a specialist, were defined as non-severe 
cases. Some severe AD patients probably underwent topical treatment and phototherapy 
because of insufficient effect of conventional systemic treatment or side effects. 
Unfortunately, they can have been misclassified as non-severe AD when using the study 
definition. Moreover, misclassification of disease severity cannot be excluded if 
comorbidities were an indication for treatment in dermatological wards, for example, if the 
patients had a mild-to-moderate AD with a flare that could not be managed at home. 
Speculatively, the latter would apply more to the older patients in the study. Historically, 
more patients were treated at dermatological wards, because there were more hospital beds 
and a lower threshold for admission. In 1970, Sweden had the highest number of hospital 
beds in Europe (all specialities included); forty years later, we had the lowest number in 
Europe (162). In addition, there is another explanation for the higher age among severe 
cases compared with non-severe cases (mean age 53.5 years vs. 41.0 years) at the end of the 
Study I. Before 2001, patients with a diagnosis of AD could only be identified in the 
inpatient register. This is a problem, since all non-severe AD cases were misclassified as 
controls before 2001. In summary, aside for the problem of misclassification of AD 
severity, some of the differences in cardiovascular comorbidities between severe and non-
severe AD cases are due to age differences between these two groups. Therefore, 
comparisons in comorbidity can only be made between cases and age-matched controls and 
not between severe AD and non-severe AD. 
In Study V, misclassification of depression cannot be excluded. The patients completed 
assessments with MADRS-S, but unfortunately, we did not have a complementary measure 
of depressive symptoms assessing the DSM-IV criteria of depression. On the other hand, a 
Swedish study has compared MADRS-S with Beck Depression Inventory II, one of the 
most commonly used instruments for screening and diagnosis of depression. It found good 
comparability and reliability across severity of depression and suggested that MADRS-S 
could be used for both diagnostic assessment and follow-up (163). 
Misclassification of comorbidities could have occurred if AD patients were more frequently 
seen in the healthcare system and, therefore, were more often diagnosed with comorbidities, 
while non-AD patients were less frequently seen and hence underdiagnosed. The strength is 
the high validity of diagnoses in NPR (96). The long follow-up time enables both cases and 
controls to receive a diagnosis regardless of one visit due to another diagnosis, although 
some degree of misclassification can never be excluded in register data. I also recognise 
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that NPR may have a low coverage for several diagnoses managed in primary care, such as 
Hashimoto’s disease and chronic urticaria. 
In the clinical studies, reporting bias may have occurred during several stages of the data 
collection. Maybe the study subjects gave an answer they thought was of interest, or 
underreported undesirable behaviours, such as high alcohol consumption. I consider this a 
minor bias, as data were collected prospectively before the research questions were defined. 
6.2.2.3 Confounding 
A confounding factor is associated with both the exposure and the outcome, but is not a link 
in the causal pathway. It is a third factor, causing a confusion of effects (161). There are 
several methods to prevent confounding, including restriction, matching, stratification and 
multivariate techniques (158). In Studies I–II, matching by age and sex was used, and 
several other possible confounders were included in the multivariable models. However, 
one of the major limitations of Studies I–II was missing data on smoking. Smoking could 
have influenced several of the associations, mainly between AD and CVD, but also 
between AD and autoimmune diseases. In Study V, it cannot be excluded that regular 
follow-ups and supporting staff motivated the patients to use more moisturisers and to 
avoid eczema triggers. This could have improved both AD and mental health. I hope this 
was a minor bias, as the observers and participants could be considered blinded to the 
hypothesis and related research questions, which were determined several months after data 
collection. 
6.2.2.4 Effect modification 
Effect modification occurs when the effect of an exposure on the outcome differs 
depending on the level or value of a third variable (164). In Studies I and II, no effect 
modification was found for the included covariates. As previously mentioned, the research 
team did not have information about smoking or obesity for the entire population. 
Therefore, it cannot be excluded that some of the associations were different between 
subgroups of AD patients, such as obese vs. non-obese or smokers vs. non-smokers. 
6.2.2.5 External validity 
The strength of the case-control studies was the population-based design with inclusion of 
the entire population. Therefore, the results can be generalised to other populations with 
similar environmental and genetic backgrounds. In the prospective clinical studies, data 
were collected in a routine dermatological setting, meaning that the results are 
representative for how systemic AD treatment affects clinical outcomes in daily clinical 
practice. This is important, as existing knowledge on effects and adverse events from 




Random error is variability of data that cannot be explained or may be due to chance (164). 
The confidence interval provides an estimate of the variability. In Studies I–II, the large 
sample sizes reduced the effect of random errors and enabled precise estimates with narrow 
confidence intervals in general. By contrast, some precision was lost in the clinical studies 
due to small study populations, especially in the subgroup analyses (Studies IV–V). In 
Study II, the Bonferroni correction might have led to a type II error when studying the 
association between AD and multiple autoimmune diseases. Therefore, p-values below the 
common critical p-value of 5% were presented in bold, to make the data more accessible 
for interpretation. By way of example, an association between AD and DM1 (p = 0.003) 
was found in the overall analysis using the common critical p-value (< 0.05), but not after 
Bonferroni correction. However, the OR was low and probably without clinical 





I. Adult patients with AD had a positive association with angina pectoris, MI, and 
ischaemic stroke compared with the general population. The association was 
attenuated after adjustment for cardiovascular comorbidities and socioeconomic 
status. 
 
II. Diabetes mellitus, hyperlipidaemia, and hypertension were more prevalent in 
patients with severe AD than in controls, and hyperlipidaemia and hypertension 
were also more prevalent in patients with non-severe AD than in controls. Subgroup 
analyses indicated that smoking was an important risk factor for CVD among severe 
AD cases. 
III. Adult patients with AD had a positive association with autoimmune diseases, 
especially disorders involving the skin, the gastrointestinal tract and/or the 
connective tissue. Having multiple autoimmune diseases resulted in a stronger 
association with AD than having only one autoimmune disease. Men with AD had a 
stronger association with RA and coeliac disease than women with AD. 
IV. Dupilumab was a very effective and safe treatment overall. Although the case-series 
was small, it was concluded that the risk of adverse events from the eyes and 
recurrence of herpes virus infections should be kept in mind, especially for patients 
with severe, long-lasting AD and previous eye disease. Dupilumab-associated 
conjunctivitis was the most common adverse event. 
V. Weight gain was an unexpected and unexplained side effect during dupilumab 
treatment of AD. 
VI. In routine dermatological care, more than half of the patients had depressive 
symptoms at the start of systemic treatment for moderate-to-severe AD, with 25% 
of them presenting with a moderate-to-severe depression and 5% with pronounced 
suicidal ideation. 
VII. Systemic treatment significantly reduced depressive symptoms, in addition to 




8 POINTS OF PERSPECTIVE 
In 2016, when we started to prepare for the clinical database (to be SwedAD), no biologics 
with indication for AD were available on the Swedish market. The research projects have 
followed the journey of a new treatment and on the way, we have revised the research 
questions. Several new questions have arisen, where the answers could potentially relieve 
the disease burden in subjects with AD and give deeper insight into the pathogenesis of this 
disease.  
I. Can optimal treatment of AD, including topical treatment and/or systemic treatment, 
have an impact on the association between AD and CVD, autoimmune disease or 
depression? And the ultimate question, is there a causal link between AD and these 
comorbidities? 
 
II. Do patients with multiple autoimmune diseases respond differently to systemic 
treatment; is there an autoimmune component making these patients more treatment-
resistant? Are there subgroups of AD patients with higher risk of CVD and/or 
autoimmune disease? 
Real-world prospective register studies might shed some light on these questions 
(I+II). It is important to establish a correct diagnosis of AD, including a severity 
grading, and to obtain detailed information on confounding factors that have been 
largely unavailable in previous register studies. 
 
III. Why did the patients with dupilumab gain weight? 
The research group will continue to prospectively follow up this novel observation. 
Did the patients represent a phenotype within the AD spectrum, possibly linked to 
disease severity, more vulnerable to this side effect? Did they have other risk factors, 
e.g., for the metabolic syndrome?  
 
IV. How can dupilumab-associated conjunctivitis be prevented? 
Anecdotal reports found artificial tears to be effective. If a cheap and benign 
recommendation, such as artificial tears, can prevent patients from adverse events 
and treatment discontinuation, this recommendation should be added to guidelines. 
However, to my knowledge, this have not been studied in larger trials. This could be 
studied in a RCT with patients randomised to prophylactic treatment. The first step 
might be to further characterise patients at risk through collaboration with an 
opthamologists. When new research data on the pathophysiology are available, there 
might be other ways to prevent this side effect. 
 
V. What is the safest treatment option for severe AD in the current COVID-19 
pandemic: conventional systemic treatment or dupilumab? 
It would be interesting to perform a cohort study using Swedish national registries to 
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ascertain incidence of COVID-19 in those receiving particular treatments. The 
findings could be important for future treatment guidelines. 
 
VI. What is the best treatment for AD? 
Treatment decision until now have often been based on disease severity and 
treatment options have been unspecific and limited. With emerging new therapies, 
this could also be based on biological pathways (endotypes) and phenotypes. We 
have just entered an era of personalised medicine, with increasing knowledge on AD 
biomarkers that can guide us to optimal treatment decisions. Another compelling 
research area is the exposome involved in AD pathogenesis (41), defined as the sum 
of external factors that an individual is exposed to during their lifetime. This includes 
numerous factors such as antenatal exposures, early life exposures, diet, allergens, 
the microbiome, urbanisation, climate, etc. Deeper understanding within this field 
might also change future treatment guidelines and preventive healthcare. It would be 
very interesting to be a small part of the ongoing research within these fields.    
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Atopisk dermatit (AD), även kallat atopiskt eksem eller böjveckseksem, är en av världens 
vanligaste kroniska inflammatoriska hudsjukdomar och drabbar upp till 20 % av alla barn 
och 10 % av vuxna. Symtomen karakteriseras av torr hud och återkommande kliande 
utslag. De allra flesta har ett milt eksem, men beroende på svårighetsgrad kan AD påverka 
flera aspekter av hälsorelaterad livskvalitet. AD kan leda till sömnstörningar orsakade av 
klåda och rivning, liksom begränsningar av arbetsliv och sociala relationer. Depression och 
självmordstankar är vanligare hos dem med AD än hos normalbefolkningen. Studier under 
de senaste åren har visat motstridiga resultat kring huruvida det även finns ett samband 
mellan AD och hjärt- och kärlsjukdomar respektive autoimmuna sjukdomar. 
Mild AD kan behandlas utvärtes. Svårare AD kan kräva ljusbehandling eller systemisk, 
invärtes behandling med t.ex. metotrexat eller cyklosporin. Systemisk behandling kan dock 
vara otillräcklig eller ge biverkningar. Nya revolutionerande kunskaper om AD har bidragit 
till utveckling av nya läkemedel under de senaste åren. Det första biologiska läkemedlet som 
godkändes i Europa 2017 har visat sig vara mycket effektivt och är ett genombrott för 
patienter med svår AD. 
Denna avhandling studerade sambandet mellan AD och hjärt- och kärlsjukdom (studie I), 
och mellan AD och autoimmuna sjukdomar (studie II) hos AD-patienter som var 15 år eller 
äldre. Detta analyserades med data från svenska nationella register. Vi jämförde 104 832 
personer som hade fått diagnosen AD med 1 022 435 friska kontroller från 
normalbefolkningen avseende exponering för hjärt-kärlsjukdom och autoimmuna 
sjukdomar. De kliniska studierna (studie III–V) undersökte effekter och biverkningar av 
systemiska läkemedel inklusive dupilumab, det första biologiska läkemedlet. Vi studerade 
även förekomst och svårighetsgrad av depression hos dem med medelsvår-svår AD (studie 
V). De kliniska studierna baserades på data från ett kvalitets- och forskningsregister för 
patienter med AD vid hudkliniken vid Karolinska Universitetssjukhuset. Registret skapades 
2017 som ett forskningsregister och lanserades 2019 som ett nationellt kvalitetsregister för 
AD (SwedAD). 
Vi upptäckte ett samband mellan AD och hjärt- och kärlsjukdom och stroke, men inte 
mellan AD och dödsfall till följd av hjärt- och kärlsjukdom. Endast de med svårast AD 
hade en signifikant ökad samsjuklighet med stroke. Patienter med svår AD hade generellt 
sett högre förekomst av diabetes mellitus (sockersjuka), höga blodfetter och högt blodtryck 
jämfört med kontroller. Rökning tycktes vara en bidragande faktor till hjärt- och 
kärlsjukdom hos dem med svår AD, men vi hade endast underlag för att analysera detta hos 
en mindre grupp kvinnor. Vi påvisade även en association mellan AD och autoimmun 
sjukdom, som var starkare ju fler autoimmuna sjukdomar man hade. De starkaste 
sambanden var mellan AD och andra autoimmuna hudsjukdomar, inflammatoriska 
magtarmsjukdomar och reumatiska sjukdomar. De kliniska studierna visade att dupilumab 
är en mycket säker och effektiv behandling, men i studie III, där patienterna hade svår AD 
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och många hade haft ögonsjukdom tidigare, utvecklade nio av tio ögonbiverkningar, varav 
sju av tio fick konjunktivit (inflammation av ögats bindhinna). Nästan alla kunde fortsatta 
med dupilumab, men fick samtidigt behandling genom ögonläkare. Vi upptäckte även en 
oväntad genomsnittlig viktuppgång på 6 kg (från 0.1 till 18 kg) hos 12 patienter som stått 
på dupilumab i mer än ett år. Vi kunde ej förklara vad denna viktuppgång berodde på. I den 
sista kliniska studien (V) såg vi att mer än hälften av dem som skulle börja med 
systembehandling av AD var deprimerade, varav 25 % hade en medelsvår depression, och 5 
% uttalade självmordstankar. Systembehandling förbättrade depressiva symptom parallellt 
med att förbättra AD. 
Sammanfattningsvis såg vi att AD hade en samsjuklighet med flera andra sjukdomar. 
Genom en ökad medvetenhet om samsjuklighet vid AD, t.ex. genom screening för 
kardiovaskulära riskfaktorer eller autoimmuna sjukdomar, kan man kanske minska 
sjukdomsbördan vid AD, framför allt hos dem med svårast hudsjukdom. Dupilumab visade 
sig vara ett mycket effektivt och generellt säkert läkemedel för AD och minskade även 
depressionssymptom. En vanlig biverkan var dock konjunktivit. Nära samarbete med 
ögonläkare rekommenderas vid ögonsymptom, då det kan öka sannolikheten att patienten 
kan fortsätta behandlingen. Genom det nationella kvalitetsregistret (SwedAD) kan 
forskningen fortsätta att följa det långsiktiga sjukdomsförloppet av AD och effekten och 
biverkningarna av läkemedel. Detta kommer att bli särskilt viktigt framöver, eftersom flera 
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